WO2003086414A1 - Structural modification of resveratrol: sodium resverastatin phosphate - Google Patents
Structural modification of resveratrol: sodium resverastatin phosphate Download PDFInfo
- Publication number
- WO2003086414A1 WO2003086414A1 PCT/US2003/011008 US0311008W WO03086414A1 WO 2003086414 A1 WO2003086414 A1 WO 2003086414A1 US 0311008 W US0311008 W US 0311008W WO 03086414 A1 WO03086414 A1 WO 03086414A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- resveratrol
- och
- nmr
- max
- stilbene
- Prior art date
Links
- 0 *c1cc(*)ccc1 Chemical compound *c1cc(*)ccc1 0.000 description 2
- LLCGHTBIDOZWAN-ACGXKRRESA-N CC(C1)[C@H]1c1ccc(C=C)cc1 Chemical compound CC(C1)[C@H]1c1ccc(C=C)cc1 LLCGHTBIDOZWAN-ACGXKRRESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
- C07C41/26—Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
- C07C41/30—Preparation of ethers by reactions not forming ether-oxygen bonds by increasing the number of carbon atoms, e.g. by oligomerisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
Definitions
- the present invention relates generally to antineoplastic compositions. More particularly this invention relates to derivatives of resveratrol, combretastatin A-4, and methods of synthesis thereof.
- Resveratrol (1) 3,4',5-trihydroxy-t « ⁇ -stilbene, is a phytoalexin found in grapes and certain other plants.
- Orsini, F., et al. Isolation, Synthesis, and Antiplatelet Aggregation of Resveratrol 3-O- ⁇ -D-glucopyranoside and Related Compounds, J. Nat. Prod. 1997, 60, 1082- 1087; Siemann, E. H., et al., Concentration of the Phytoalexin Resveratrol in Wine, Amer. J. of Enology and Viticulture 1992, 43, 49-52; Goldberg, D., et al., A Global Survey of Trans- resveratrol Concentrations in Commercial Wines, Clin.
- the compound exhibits a variety of useful biological properties including antileukemic, antibacterial, antifungal, antiplatelet aggregation, and coronary vasodilator activities.
- useful biological properties including antileukemic, antibacterial, antifungal, antiplatelet aggregation, and coronary vasodilator activities.
- This triphenolic stilbene (1) also has strong antioxidative and anti-inflammatory activities associated with chemopreventive properties. (Pattichis, K., et al., Inhibition of Human LDL Oxidation by Resveratrol, Lancet 1993, 1103-1108; Goldberg, D., More on Antioxidant Activity of Resveratrol in Red Wine, Clin. Chem.
- Resveratrol (1) has been suggested as a possible cancer chemopreventive agent based on inhibitory effects on tumor initiation, promotion, and progression. (Jang, M., et al., Cancer
- resveratrol (1) has displayed cancer cell growth inhibition in vitro.
- Choanvitayapongs, S., et al. Amelioration of Oxidative Stress by Antioxidants and Resveratrol in PC12 cells, NeuroReport 1997, 8, 1499-1502; Mgbonyebi, O., et al., Antiproliferative Effect of Synthetic Resveratrol on Human Breast Epithelial Cells, Int. J. Oncol.
- resveratrol (1) has recently been shown to induce apoptosis and decrease expression of Bcl-2 in the human leukemia HL-60 cell line.
- Resveratrol an Antioxidant Present in Red Wine, Induces Apoptosis in Human Promyelocytic Leukemia (HL-60) cells, Cancer Lett.
- resveratrol Tetramers from Vatica Diospyoides. J. Org. Chem. 1999, 64, 6976-6983; Ohyama, M., et al., Antitumor Agents 200. Cytotoxicity of Naturally Occurring Resveratrol Oligomers and their Acetate Derivatives, Bioorg. Med. Chem. Lett. 1999, 9, 3057-3060.
- Other biological properties of resveratrol (1) include activities targeting cyclooxygenase, tyrosine kinase (PTK), and protein kinase C (PKC), as well as selective human cytochrome P450 1 Al
- Resveratrol is a Selective Human Cytochrome P450 1 Al Inhibitor, Biochem. Biophys. Res. 1999, 262, 20-24; Cichewicz R. H., et al., Biotransformation of resveratrol to piceid by Bacillus cereus, J. Nat. Prod. 1998, 61, 1313-1314.
- the prime object of the present invention was to discover pharmaceutically active derivatives of resveratrol.
- Another object of the present invention was to discover pharmaceutically active derivatives of combretastatin A-4.
- a starting material in stilbene synthesis is 4-methoxybenzyltriphenylphosphonium bromide (3) that was obtained as follows: To a solution of 4-methoxybenzyl bromide (22.4 g) in toluene (200 ml) was added triphenylphosphine (29.2 g). The solution was heated at reflux for 12 hours under argon. The resulting precipitate was collected and recrystallized from ethanol as colorless crystals (44.0 g, 85.3%) mp 235-237°C, (lit 19 mp 234°C).
- the oil was separated by flash column chromatography (49:1 hexane:ethyl acetate).
- Resveratrol (1) was obtained from a stilbene in the following manner. To stilbene 4b (3.1 g) in anhydrous dichloromethane (150 ml) at -78°C was added (dropwise) boron tribromide (1.0 M, 34.5 ml), and the resulting red solution was stined under argon for 30 minutes. The solution was poured into water and extracted with dichloromethane.
- the compound 4-(tert-butyldiphenylsilyloxy)-benzaldehyde (5a) was obtained in the following manner. To a solution of 4-hydroxybenzaldehyde (3.2 g) in dimethylformamide (50 ml) was added imidazole (1.9 g, 1.1 equiv.). The solution was stined for 15 minutes, tert- butyldiphenylsilyl chloride (7.4 ml, 1.1 equiv.) was added, and the light brown solution was stined for 3 hours. The reaction mixture was poured into water and extracted with ethyl acetate. Removal of the solvent in vacuo from the organic phase provided a brown oil. The oil was
- the compound 4-(tert-butyldiphenylsilyloxy)-benzyl alcohol (6) was obtained in the following manner. To a solution of aldehyde 5a (4.7 g) in methanol (100 ml) at 0°C was slowly added sodium borohydride (0.59 g, 1.2 eq.). After stirring for 2 hours the reaction mixture was
- the compound 4-(tert-butyldiphenylsilyloxy)-benzyltriphenylphosphonium bromide (8) was obtained in the following manner. To a solution of bromide (7) (4.3 g) in toluene (100 ml) was added triphenylphosphine (13.2 g).
- the compound 3,5-di(tert-butyldimethylsilyloxy)-benzaldehyde (9a) was obtained in the following manner.
- DIEA (7.7 ml, 2 equiv.) was added to a solution of 3,5- dihydroxybenzaldehyde (3.0 g) in dimethylformamide (30 ml), and the solution was stined for 15 minutes.
- the silyl chloride (7.5g) was added and the light brown solution stined for 16 hours. The mixture was poured into water and extracted with dichloromethane.
- the compound identified as cw-Resveratrol (10) was obtained as follows: the Wittig reaction was performed as summarized above using 5 mmol of phosphonium salt, and the TBDPS-protected stilbene isomers were isolated as a mixture. The mixture was dissolved in tetrahydrofuran and treated with TBAF (3.0 eq), being stined for 1 hour. The product was purified by gravity column chromatography (3:2 hexane:ethyl acetate) and yielded 0.21 g of the cw-isomer as a colorless solid and 0.24 g of a mixture of isomers (95.1%): mp 172-174°C (lit 12c mp 170-174°C).
- Hunig's base (10.2 ml, 2 eq) was added to a solution of 4-hydroxybenzaldehyde (6.0 g) in dimethylformamide (50 ml) to obtain 4-(tert)-butyldimethylsilyloxy-benzaldehyde (5b).
- the solution was stined for 15 minutes, tert-butyldimethylsilyl chloride (8.9 g) was added, and the clear light brown solution was stined for 15 hours.
- the reaction mixture was poured into water,
- the mixture was stined at -10°C for 30 minutes under argon, dibenzylphosphite (5.0 ml, 1.5 equiv.) was added, .and the solution was stined for 12 hours and then poured into 0.5 M monobasic potassium phosphate. The mixture was extracted with ethyl acetate and removal of solvent in vacuo from the organic phase yielded a tan oil.
- bromophenol (4.15 g) was dissolved in anhydrous dichloromethane (40 ml), then imidazole (1.63 g) and tert-butyldimethylsilyl chloride (3.61 g) were added.
- the cream suspension was stined under argon for 12 hours and the reaction was terminated with addition of water.
- the mixture was extracted with ethyl acetate.
- Alcohol 15b (0.12g) was deprotected with TBAF as for the stilbenes above to provide 4'- Hydroxy-3,5-dimethoxybenzhydrol 15c as a colorless oil (0.03 g, 42%): EIMS m/z 260 (M + ),
- Alcohol 15b (0.58 g) led to 4'-(ter/-butyldimethylsilyloxy)-3,5-dimethoxybenzophenone 16b as a colorless oil (0.46 g, 80%): EIMS m/z 372 (M + ), 315, 165, 157, 137, 28; IR (KBr, cm "1 )
- Alcohol 15d (0.72 g) provided 3,5-di-(tert-butyldimethylsilyloxy)-4'- methoxybenzophenone 16d as a colorless oil (0.64 g, 90%): EIMS m/z 472 (M + ), 457, 415, 359,
- the cytotoxicity data from the resveratrol stilbenes was determined.
- the c ⁇ s-isomer of resveratrol (lb) exhibited slightly less inhibitory effects on the cancer cell lines tested than did the tranj-isomer.
- the trimethoxy stilbenes 4a,b are between 10-100 fold more active against tumor cell lines than the parent compound resveratrol (1), with compound 4a (the ⁇ ' s-stilbene) far more active than 4b.
- the synthesized prodrug 14n was essentially identical to 14c in its effects on the growth of cancer cells. From the known antimitotic activity of combretastatin A-4 (2a) and phenstatin (2c) and their potent interactions with tubulin, it seemed possible that the most cytotoxic compounds prepared in the cunent series would also inhibit this important cellular protein.
- Combretastatin A-4 (2a) binds in the colchicine site of tubulin and is exceptionally potent as an inhibitor of the binding of radiolabeled colchicine to tubulin.
- Combretastatin A-4 (2a) displayed its usual potency, inhibiting colchicine binding by 98% when the two drugs were present in equimolar (5 ⁇ M) concentrations and by 91% when 2a was present at 2 ⁇ M (the tubulin
- Resveratrol (1) contained in the roots of Polygonum cuspidatum has apparently been used in Chinese and Japanese traditional medicine as a treatment for gononhea.
- its activity against the etiologic agent of gononhea, Neisseria gonorrhoeae was demonstrated in broth microdilution assays (Table IV).
- Stilbene production has been conelated with the resistance of grape leaves to fungal infection.
- the tubulin polymerization assay was performed as previously described. 24 The tubulin concentration was 10 ⁇ M, with varying drug concentrations, as required, to obtain IC 5 o values. Extent of assembly after 20 min at 30°C was the parameter measured. The colchicine binding assay was performed as earlier reported. 27 The tubulin concentration was 1.0 ⁇ M, the [3H] colchicine concentration was 5.0 ⁇ M, and the potential inhibitor concentrations were as indicated. Binding of colchicine was measured following a 10 min incubation at 37°C.
- Microorganism 1 4a 14c 14h 14k 14u 15c 16a 16c 16e I6g 16! 16k
Abstract
Described herein are novel compounds having antineoplastic and antimicrobial activity, obtained via structural modifications of resveratrol and combretastatin A-4, methods for synthesis of these compounds, and their use in pharmaceutical composition and for use in the treatment of mammals having cancer. Examples of the novel compounds are: (Z)- and (E)- 3,4',5-trimethoxystilbene (4a, 4b); (Z)- and (E)-3,5-dimethoxy-4'-hydroxystilbene (14c, 14d); (Z)-and (E)-3-hydroxy-4',5-dimethoxystilbene (14g, 14h); (Z)-and (E)-3,5-dihydroxy-4'-methoxy-stilbene (14k, 14l); sodium resverastatin dibenzyl phosphate ((Z)-3,5-dimethoxy-4-[O-bis(benzyl)phosphoryl]-stilbene) (14m); and sodium resverastatin phosphate (14n).
Description
TITLE OF THE INVENTION Structural Modification of Resveratrol: Sodium Resverastatin Phosphate RELATED APPLICATION DATA This application is based on and claims the benefit of U.S. Provisional Patent Application No. 60/371,782 filed on April 10, 2002.
GOVERNMENT INTEREST Financial assistance for this invention was provided by the United States Government, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Department of Health
and Human Services Outstanding Investigator Grant Numbers CA44344-05-12 and RO1 CA90441-01. Thus, the United States Government has certain rights in this invention.
FIELD OF THE INVENTION The present invention relates generally to antineoplastic compositions. More particularly this invention relates to derivatives of resveratrol, combretastatin A-4, and methods of synthesis thereof.
BACKGROUND OF THE INVENTION The antitumor properties of a series of structurally simple compounds derived from tropical and subtropical trees of the family Combretaceae are under ongoing investigation. The genus Combretum contains 25 species used in the traditional medical practices of Africa and India. The South African bush willow Combretum caffrum was used by the Zulu and other Southern African people as a charm to ward off enemies and in traditional medical practices.
Combretum caffrum (Eckl. Zehy.) Kuntze collected in 1973 and recollected in 1979 afforded extracts that showed activity in the astrocyte reversal (9 ASK) and murine lymphocytic leukemia screening assays of the National Cancer Institute of the U.S.A. Historically, this
1398874.1/12504.012 9
extract was the first to be successfully fractionated by means of the 9ASK system. In 1982 the isolation of the first member of the combretastatin series was disclosed. Also disclosed was its structure and later synthesis. (Pettit, G. R., et al., Isolation and Structure of Combretastatin, CAn. J. Chem. 1982, 60, 1374-1376; Pettit, G. R., et al., Synthesis of Natural (-) - combretastatin, J. Org. Chem. 1985, 50, 3404-3406.) Subsequently, a number of additional cancer cell line active constituents were isolated. These investigations eventually led to applicant's isolation, structure and synthesis of the -stilbene combretastatin A-4 (2a) and its phosphate prodrug (2b). (Pettit, G.R., et al., Isolation and Structure of the Strong Cell Growth and Tubulin Inhibitor Combretastatin A-4, Experentia, 1989, 45, 209-211; Pettit, G. R, et al., Antineoplastic agents 291. Isolation and Synthesis of Combretastatin A-4, A-5, and A-6, J. Med. Chem. 1995, 38, 1666-1672; Ndayikcngu kiyc, II., ct al., Alkoxylalcd p- phenylenevinylene Oligomers: Synthesis and Spectroscopic and Electrochemical Properties, Tetrahedron 1997, 53, 13811-13828.) The latter has been shown to selectively damage tumor neovasculature with induction of extensive blood flow shutdown in the metastatic tumor compared to normal tissues.
For example, six hours following treatment using the murine CaNT adenocarcinoma and a single i.p. injection of combretastatin A-4 prodrug (100 mg/kg), vascular function shutdown in the tumor was rapid, ineversible and extensive (8). (Ndayikengurukiye, H., et al., Alkoxylated p-phenylenevinylene Oligomers: Synthesis and Spectroscopic and Electrochemical Properties. Tetrahedron 1997, 53, 13811-13828.) In November, 1998 four Phase I human cancer trials were initiated, two in the United States and two in England. Cunent clinical trials (9) have been encouraging and Phase II human cancer clinical trials have been or will be initiated soon. (Cushman, M., et al., Synthesis and Evaluation of Analogues of (Z) - 1 - (4-methoxyphenyl) -2-
1398874.1/12504.012 7
(3, 4, 5-trimethoxyphenyl) ethane as Potential Cytotoxic and Antimitotic Agents, J. Med. Chem- 1992, 35, 2293-2306.)
The need for such compounds is both critical and ongoing. The isolation of such valuable compounds is the purpose of the present invention.
BRIEF SUMMARY OF THE INVENTION
Resveratrol (1), 3,4',5-trihydroxy-t «^-stilbene, is a phytoalexin found in grapes and certain other plants. (Orsini, F., et al., Isolation, Synthesis, and Antiplatelet Aggregation of Resveratrol 3-O-β-D-glucopyranoside and Related Compounds, J. Nat. Prod. 1997, 60, 1082- 1087; Siemann, E. H., et al., Concentration of the Phytoalexin Resveratrol in Wine, Amer. J. of Enology and Viticulture 1992, 43, 49-52; Goldberg, D., et al., A Global Survey of Trans- resveratrol Concentrations in Commercial Wines, Clin. Chem. 1995, 46, 159-1665; Adesanya, S.A., et al., Stilbene Derivatives from Cissus quandrangularis. J. Nat. Prod. 1999, 62, 1694- 1695; Arichi, H., et al., Effects of Stilbene Components of the Root of Polygonum cuspidatum Sieb. Et Zucc. On Lipid Metabolism, Chem. andPharm. Bull. 1982, 30, 1766-1770; Ingham, J., 3,5,4' - trihydroxystilbene as a Phytoalexin from Groundnuts (Arachis hypogaea). Phytochem. 1976, 15, 1791-T793.)
The compound exhibits a variety of useful biological properties including antileukemic, antibacterial, antifungal, antiplatelet aggregation, and coronary vasodilator activities. (Jeandet, P., et al., The Production of Resveratrol by Grape Berries in Different Developmental Stages, Am J. ofEnology and Viticulture 1991, 42, 41-46; Manila, E., et al., Anti-leukaemic compounds Derived from Stilbenes in Picea abies Bark, Phytochem. 1993, 33, 813-816; Kubo, M., et al., Shoyayugaku Zasshi 1981, 35, 58; Creasy, L., et al., Phytoalexin Production Potential of Grape Berries, J. of the Am. Soc. of Horticultural Science 1988, 113, 230-234; Langcake, C, et al.,
1398874.1/12504.012
Identification of Pterostilbene as a Phytoalexin from Vitis vinifera Leaves, Phytochemistry 1979, 18, 1025-1027; Langcake, R., et al., The Relationship of Resveratrol Production to Infection of Grapevine Leaves by Botrytis cenerea, Vitis 1979 18:244-253; Chung, M., et al., An Antiplatelet Principle of Veratrum formosanum, Planta Medica 1992, 58, 274-276; Inamori, Y., et al., The Ichthyotoxicity and Coronary Vasodilator Action of 3,3' - dihydroxy-α, β- diethylstilbene, Chem. Pharm. Bull. 1987, 35, 887-890.) This triphenolic stilbene (1) also has strong antioxidative and anti-inflammatory activities associated with chemopreventive properties. (Pattichis, K., et al., Inhibition of Human LDL Oxidation by Resveratrol, Lancet 1993, 1103-1108; Goldberg, D., More on Antioxidant Activity of Resveratrol in Red Wine, Clin. Chem. 1996, 42, 113-114; Pace-Asciak, C, et al., The Red Wine Phenolics Trans-resveratrol and Quercetin Block Human Platelet-Aggregation and Eicosanoid Synthesis-implications for Protection Against Coronary Heart-Disease, Clinical Chemica Acta 1995, 235, 207=219.) Resveratrol (1) has been suggested as a possible cancer chemopreventive agent based on inhibitory effects on tumor initiation, promotion, and progression. (Jang, M., et al., Cancer
Chemopreventive Activity of Resveratrol. A natural product Derived from Grapes, Science 1997, 275, 218-220; Uenobe, F., Antimutagenic Effects of Resveratrol Against Trp-P-1, Mutation Res. 1997, 373, 197-200.)
In addition to antitumor promoting activity, resveratrol (1) has displayed cancer cell growth inhibition in vitro. (Chanvitayapongs, S., et al., Amelioration of Oxidative Stress by Antioxidants and Resveratrol in PC12 cells, NeuroReport 1997, 8, 1499-1502; Mgbonyebi, O., et al., Antiproliferative Effect of Synthetic Resveratrol on Human Breast Epithelial Cells, Int. J. Oncol. 1998, 12, 865-869; Jayatilake, G., et al., Kinase Inhibition From polygonum cuspidatum 1993, 56, 1805-1810; Chun, Y., et al., Resveratrol is a Selective Human Cytochrome P450 1A1
1398874.1/12504.012 *s
inhibitor, Biochem. Biophys. Res. 1999, 262, 20-24.) Importantly, resveratrol (1) has recently been shown to induce apoptosis and decrease expression of Bcl-2 in the human leukemia HL-60 cell line. (Surh, Y. J., et al., Resveratrol, an Antioxidant Present in Red Wine, Induces Apoptosis in Human Promyelocytic Leukemia (HL-60) cells, Cancer Lett. 1999, 140, 1-10.) Furthermore, the resveratrol tetramers vatdiospyridol and resveratrol oligomers recently isolated from Asian plants have shown significant inhibition of the growth of several cancer cell lines. (Seo, H., et
al., Resveratrol Tetramers from Vatica Diospyoides. J. Org. Chem. 1999, 64, 6976-6983; Ohyama, M., et al., Antitumor Agents 200. Cytotoxicity of Naturally Occurring Resveratrol Oligomers and their Acetate Derivatives, Bioorg. Med. Chem. Lett. 1999, 9, 3057-3060.) Other biological properties of resveratrol (1) include activities targeting cyclooxygenase, tyrosine kinase (PTK), and protein kinase C (PKC), as well as selective human cytochrome P450 1 Al
inhibition and microbiological transformation to resveratrol 3-O-β-D-glucoside. (Jang, M., et al.,
Cancer Chemopreventive Activity of Resveratrol. A Natural Product Derived from Grapes, Science 1997, 275, 218-220; Jayatilake, G., et al., Kinase Inhibition from Polygonum cuspidatum, J. Nat. Prod. 1993, 56, 1805-1810; Chun, Y., et al., Resveratrol is a Selective Human Cytochrome P450 1 Al Inhibitor, Biochem. Biophys. Res. 1999, 262, 20-24; Cichewicz R. H., et al., Biotransformation of resveratrol to piceid by Bacillus cereus, J. Nat. Prod. 1998, 61, 1313-1314.)
The compounds in question were isolated/synthesized in the manner generally described below. These compounds were discovered to have the properties noted.
Accordingly the prime object of the present invention was to discover pharmaceutically active derivatives of resveratrol.
1398874.1/12504.012
Another object of the present invention was to discover pharmaceutically active derivatives of combretastatin A-4.
DESCRIPTION OF THE PREFERRED EMBODIMENTS The compounds discovered were obtained in the following manner, using the following lexicon that should be familiar to one of ordinary skill in the art.
All solvents were redistilled. Hunig's base and proton sponge refer respectively to N,N,- diisopropylcthylaminc and l,8-b-_.-(dimethylamino)-naphthalcnc. Both the course and products from reactions were monitored by thin-layer chromatography using Analtech silica gel GHLF uniplates. All reactions were carried out under an inert atmosphere. Solvent extracts of aqueous solutions were dried over anhydrous sodium sulfate unless otherwise noted. Flash column chromatography was performed using silica gel (230-400 mesh ASTM).
Melting points were recorded employing an Electrothermal 9100 digital melting point apparatus and are unconected. The IR spectra were obtained using a Mattson FTIR model 2020 instrument. Low-resolution mass spectral data were collected using a Varian MAT 312 instrument (EIMS). The high-resolution FAB spectra were obtained employing a Kratos MS-50 spectrometer. All H and C-ΝMR spectra were determined using a Varian Gemini 300 MHz instrument with CDC13 (TMS internal reference) as solvent unless otherwise noted. The 31P- ΝMR spectra were measured in CDC13 with 85% H3PO4 as an external standard employing a Varian Unity 500 MHz instrument.
1398874.1/12504.012
The following schemes and structural formulae of identified compounds, set forth at the end of this application, were used. Where practical general procedures for certain classes of compounds are also set forth below.
A starting material in stilbene synthesis is 4-methoxybenzyltriphenylphosphonium bromide (3) that was obtained as follows: To a solution of 4-methoxybenzyl bromide (22.4 g) in toluene (200 ml) was added triphenylphosphine (29.2 g). The solution was heated at reflux for 12 hours under argon. The resulting precipitate was collected and recrystallized from ethanol as colorless crystals (44.0 g, 85.3%) mp 235-237°C, (lit19 mp 234°C).
The general procedure for the stilbene syntheses was as follows. To the phosphonium bromide (1-35 mmol) in anhydrous tetrahydrofuran (5-200 ml) at -78°C was added w-butyl lithium (2.44 M, 1.0 equiv.), and the resulting red solution was stined under argon for 2-4 hours. A solution of the aldehyde (1.0 equiv.) in tetrahydrofuran was added dropwise over 30 minutes and the mixture stined for 6-15 hours. The resulting cream suspension was poured into water and extracted with dichloromethane. The organic phase was washed with water and removal of the solvent in vacuo afforded a tan oil. The oil was separated by flash column chromatography (49:1 hexane:ethyl acetate). The cis stilbene eluted first as a clear oil followed by the trans isomer as a colorless sold or oil (TBDMS protected).
By following the above general procedure, 3,4',5-trimethoxystilbene (4a,b) was obtained in the following manner. Reaction of phosphonium bromide (12.5 g) (3) and 3,5- dimethoxybenzaldehyde (4.5 g) led to cis stilbene (4a) as a clear oil (3.56 g) and the trans isomer (4b) as a colorless sold (3.08 g), 91% total yield: (Z) isomer (4a) IR neat, cm"1 vmax 3449, 2957,
2836, 1591, 1250, 1065, 640; 1H-NMR δ 6.22 (2H, dd, J= 2.4, 8.7 Hz), 6.77 (2H, dd, J= 2.4, 8.7 Hz), 6.53 (1H, d, J= 12.0 Hz), 6.45 (1H, d, J= 12.0 Hz), 6.44 (2H, d, J= 2.1 Hz), 6.32 (1H,
1398874.1/12504.012
t, J= 2.1 Hz), 3.78 (3H, s, OCH3), 3.67 (6H, s, OCH3 x 2); (E) isomer (4b) mp 57-58°C, (lit20 mp 55-56°C).
Resveratrol (1) was obtained from a stilbene in the following manner. To stilbene 4b (3.1 g) in anhydrous dichloromethane (150 ml) at -78°C was added (dropwise) boron tribromide (1.0 M, 34.5 ml), and the resulting red solution was stined under argon for 30 minutes. The solution was poured into water and extracted with dichloromethane. The organic phase was washed with water and removal of the solvent in vacuo afforded a tan oil, which was separated by flash column chromatography (l:l/hexane: ethyl acetate) to afford a colorless sold (2.26 g, 86%): mp 260°C (lit12c mp 260°C).
The compound 4-(tert-butyldiphenylsilyloxy)-benzaldehyde (5a) was obtained in the following manner. To a solution of 4-hydroxybenzaldehyde (3.2 g) in dimethylformamide (50 ml) was added imidazole (1.9 g, 1.1 equiv.). The solution was stined for 15 minutes, tert- butyldiphenylsilyl chloride (7.4 ml, 1.1 equiv.) was added, and the light brown solution was stined for 3 hours. The reaction mixture was poured into water and extracted with ethyl acetate. Removal of the solvent in vacuo from the organic phase provided a brown oil. The oil was
separated by flash column chromatography (1:0 — 19:1 hexane:ethyl acetate) to afford the aldehyde (5a) as a colorless solid (6.4 g, 68%):mp 103-105°C IR (neat, cm"1) vmax 3399, 2932,
2859, 1699, 1599, 1506, 1273, 1157, 910; 1H-NMR δ 9.80 (1H, s, CHO), 7.69 (4H, m, Ar-H),
7.64 (2H, d, J= 8.7 Hz), 7.40 (6H, m, Ar-H), 6.86 (2H, d, J=8.7 Hz), 1,11 (9Hm sm C(CH3)3), Anal. (C23H24O2Si) C, H.
The compound 4-(tert-butyldiphenylsilyloxy)-benzyl alcohol (6) was obtained in the following manner. To a solution of aldehyde 5a (4.7 g) in methanol (100 ml) at 0°C was slowly added sodium borohydride (0.59 g, 1.2 eq.). After stirring for 2 hours the reaction mixture was
1398874.1/12504.012
poured into water, solvent reduced to a minimum, extracted with ethyl acetate and the solvent
removed in vacuo to give 4.1 g of a clear oil (88%); IR (neat, cm"1) vmax 3346, 2932, 2859, 1609,
1510, 1427, 1256, 1113, 918; 1H-NMR δ 7.72 (4H, m, Ar-H), 7.39 (6H, m, Ar-H), 7.10 (2H, d, J = 8.7 Hz), 6.76 (2H, d, J= 8.7 Hz), 4.55 (2H, s, CH2), 1.11 (9H, s, C(CH3)3). Anal.
(C23H26O2Si) C, H.
The following procedure was used to obtain 4-(tert-butyldiphenylsilyloxy)-benzyl bromide (7). Phosphorus tribromide (0.5 ml) was slowly added to a solution of the alcohol 6 (4.0 g) in dichloromethane (75 ml) at 0°C, and stirring was continued for 12 hours. The reaction
mixture was poured into aqueous sodium bicarbonate, extracted with dichloromethane and the
solvent removed in vacuo to afford 4.3 g of a colorless solid (89%): EIMS m/z 426 (M+, 81Br),
424 (M+ 79Br), 390, 369, 367, 345, 289, 135: IR (neat.cm"1) vmax 3397, 3073, 2932, 2859, 1607,
1510, 1427, 1263, 1113, 918; ]H-NMR δ 7.72 (4H, m, Ar-H), 7.39 (6H, m, Ar-H), 7.13 (2H, d, J
= 8.4 Hz) 6.72 (2H, d, J= 8.4 Hz), 4.42 (2H, s, CH2), 1.11 (9H, s, C(CH3)3). 13C-NMR (75.5
MHz) δ 155.6, 135.4, 132.4, 130.1, 129.9, 127.7, 119.9, 34.0, 26.5, 19.5. Anal. (C23H25BrOSi) C, H.
The compound 4-(tert-butyldiphenylsilyloxy)-benzyltriphenylphosphonium bromide (8) was obtained in the following manner. To a solution of bromide (7) (4.3 g) in toluene (100 ml) was added triphenylphosphine (13.2 g). After heating at 100°C for 2 hours, the reaction mixture was cooled to room temperature, and the product was collected and recrystallized from ethanol to yield 6.1 g of a colorless solid (89%) mp 233°C; FABMS m/z 607.2583 (M+-Br), IR (neat, cm"1) vmax 3385, 3054, 2934, 2859, 2787, 1607, 1512, 1437, 1273, 1111, 924; 1H-NMR δ 7.61
(19H, m, Ar-H), 7.30 (6H, m, Ar-H), 6.76 (2H, dd, J= 2.4, 8.7 Hz) 6.51 (2H, d, J= 8.7 Hz), 5.18
(2H, s, CH2), 1.04 (9H, s, C(CH3)3). 13C-NMR (75.5 MHz) δ 155.7, 135.3, 134.7, 134.7, 134.3,
1398874.1/12504.012 J Q
132.3, 132.3, 130.0, 129.8, 127.6, 120.2, 120.1, 118.9, 118.9, 118.1, 117.3, 30.5, 30.1, 26.5, 19.4.
Anal. (C4ιH40BrOSi) C, H.
The compound 3,5-di(tert-butyldimethylsilyloxy)-benzaldehyde (9a) was obtained in the following manner. DIEA (7.7 ml, 2 equiv.) was added to a solution of 3,5- dihydroxybenzaldehyde (3.0 g) in dimethylformamide (30 ml), and the solution was stined for 15 minutes. The silyl chloride (7.5g) was added and the light brown solution stined for 16 hours. The mixture was poured into water and extracted with dichloromethane. Removal of the solvent in vacuo yielded a brown oil that was separated by flash column chromatography (9:1 hexane:ethyl acetate) to yield the disilylether as a tan oil (7.6 g, 94%): EIMS m/z 366 (M+), 309,
267, 239, 133,73; IR (KBr, cm"1) vmax 2957, 2861, 2805, 2710, 1705, 1385, 831; 1H-NMR δ 9.85
(1H, s, CHO), 6.95 (2H, d, J= 2.1 Hz), 6.58 (1H, t, J= 2.1 Hz), 0.99 (18H, s, C(CH3)3 x 2), 0.22 (12H, s, Si(CH3)2 x 2).
The compound identified as cw-Resveratrol (10) was obtained as follows: the Wittig reaction was performed as summarized above using 5 mmol of phosphonium salt, and the TBDPS-protected stilbene isomers were isolated as a mixture. The mixture was dissolved in tetrahydrofuran and treated with TBAF (3.0 eq), being stined for 1 hour. The product was purified by gravity column chromatography (3:2 hexane:ethyl acetate) and yielded 0.21 g of the cw-isomer as a colorless solid and 0.24 g of a mixture of isomers (95.1%): mp 172-174°C (lit12c mp 170-174°C).
Hunig's base (10.2 ml, 2 eq) was added to a solution of 4-hydroxybenzaldehyde (6.0 g) in dimethylformamide (50 ml) to obtain 4-(tert)-butyldimethylsilyloxy-benzaldehyde (5b). The solution was stined for 15 minutes, tert-butyldimethylsilyl chloride (8.9 g) was added, and the clear light brown solution was stined for 15 hours. The reaction mixture was poured into water,
1398874.1/12504.012 \ \
extracted with dichloromethane and the solvent removed in vacuo to afford a brown oil. The oil was separated by vacuum distillation to yield aldehyde 5b as a colorless oil (8.4 g, 73%): IR
(neat, cm"1) vmax 3385, 2932, 2859, 1699, 1599, 1508, 1273, 1155, 909; 1H-NMR δ 9.88 (IH, s,
CHO), 7.79 (2H, d, J= 8.4 Hz), 6.94 (2H, d, J= 8.4 Hz), 0.98 (9H, s, C(CH3)3), 0.25 (6H, s, Si(CH3)2). Anal. (C,3H20O2Si) C, H.
To obtain 3,5-dimethoxybenzyltriphenylphosphonium bromide (13) 3,5 - dimethoxybenzaldehyde (10 g) in methanol was reduced with sodium borohydride, the oily product 11, (9.6 g, 93% yield) was treated (0°, 12 hours) with phosphorous tribromide (2.7 ml), and to its resulting bromide 12 (11.6 g, 89%) in toluene (200 ml) was added triphenylphosphine (13.2 g). After heating at reflux for 12 hours the mixture was cooled to room temperature. The product was collected and recrystallized from ethanol to yield 22.8 g of a colorless solid (92%)
mp 275°C, lit12c mp 266-268°C; Η-NMR δ 7.70 (15H, m), 6.33 (2H, d, J= 2.1 Hz), 6.30 (IH, t,
J= 2.1 Hz), 5.30 (2H, d, J= 14.4 Hz), 3.53 (6H, s, OCH3 x 2).
To obtain 4'-(tert-butyldimethylsilyloxy)-3,5-dimethoxy-stilbene (14a,b), phosphonium bromide 13 (6.9 g) in anhydrous tetrahydrofuran (40 ml) at 78°C was treated with «-butyl lithium 2.5 M, 5.6 ml) and aldehyde 5b (3.3 g) in tetrahydrofuran (10 ml) according to the general Wittig-stilbene procedure (see above). (Z)-isomer (14a): EIMS m/z 370 (M+), 355, 313,
298,157; IR (KBr, cm"1) vmax 2932, 2857, 1591, 1508, 1262, 1155, 914; 1H-NMR δ 7.14 (2H, d,
J= 8.5 Hz), 6.70 (2H, d, J= 8.5 Hz), 6.51 (IH, d, J= 12.0 Hz), 6.43 (IH, d, J= 12.0 Hz), 6.42 (2H, d, J= 2.0 Hz), 6.31 (1 H, t, J= 2.0 Hz), 3.65 (6H, s, OCH3 x 2), 0.96 (9H, s, C(CH3)3), 0.17
(6H, s Si(CH3)2); 13C-NMR (75.5 MHz) δ 160.51, 154.87, 139.40, 130.27, 130.21, 128.76,
119.77, 106.57, 99.81, 55.17, 25.65, 18.22, -4.45. Anal. (C22H30O3Si) C,H. (E) isomer (14b): EIMS m/z 370 M+), 355, 313, 255 165 73; IR (KBr, cm"1) vmax 2955, 2859, 1595, 1508, 1263,
1398874,1/12504.012 12
1154, 914, 839; 1H-NMR δ 7.40 (2H, d, J= 8.5 Hz). 7.05 (IH, d, J= 16.0 Hz), 6.92 (IH, d, J= 16.0 Hz), 6.85 (2H, d, J= 8.5 Hz), 6.66 (2H, d, J= 2.5 Hz), 6.39 (IH, t, J= 2.5 Hz), 3.84 (6H, s, OCH3 x 2), 1.01 (9H, s, C(CH3)3), 0.23 (6H, s, Si(CH3)2); 13C-NMR (75.5 MHz) δ 160.9, 155.7, 139.7, 130.5 128.8, 127.7, 126.7, 120.3, 104.3, 99.6, 55.3, 25.7, 18.2, -4.4. Anal. (C22H30O3Si) C, H.
(Z) and (E)-3,5-dimethoxy-4'-hydroxy-stilbene (14c and d) and General Silyloxy Deportation Procedure were performed as follows. To a solution of the silyloxy protected (Z)- stilbene (14a, 1.2 g) in anhydrous tetrahydrofuran (20 ml) was added tetrabutylammonium fluoride (1 M, 3.4 ml). The clear light yellow solution was stined for 45 minutes, poured into water, extracted with dichloromethane and the solvent removed in vacuo to provide a tan oil. The oil was separated by gravity column chromatography (4: 1 hexane-ethyl acetate) to afford cis stilbene 14c as a yellow oil (88%): IR (neat, cm1) vmax 3385, 3005, 2940, 2837, 1591, 1512, 1456, 1152 1065, 679; 1H-NMR δ 8.01 (IH, s, OH), 7.15 (2H, d, J= 8.7 Hz), 6.71 (2H, d, J=
8.7 Hz). 6.51 (IH, d, J= 12.6 Hz), 6.43 (2H, d, J= 2.5 Hz), 6.42 (IH, d, J= 12.6 Hz), 6.31 (2H, d, J= 2.5 Hz), 3.66 (6H s, OCH3 x 2). Anal. (Cι6Hι6O3) C, C, H. (E)-3,5-dimethoxy-4'- hydroxy-stilbene (14d) was similarly prepared from stilbene 14b (0.5 g) and tetrabutylammonium fluoride (1M, 1.3 ml) in anhydrous tetrahydrofuran (10 ml) was added to yield 0.8 g of yellow oil (90%): IR (neat, cm"1) vmax 3385, 3005, 2940, 2837, 1591, 1512, 1456, 1152, 1065,
961; Η-NMR δ 8.01 (IH, s, OH), 7.44 (2H, d, J= 8.7 Hz), 7.18 (IH, d, J= 16.5 Hz), 6.98 (IH, d, J= 16.5 Hz), 6.85 (2H, d, J= 8.7 Hz), 6.73 (2H, d, J= 2.1 Hz), 6.38 (IH, t, J= 2.1 Hz), 5.25 (IH, bs, OH), 3.81 (6H, s, OCH3 x 2).
Unless otherwise noted the following intermediates and stilbene objectives were prepared by the preceding general methods for silyloxy protection, Wittig reaction and deprotection. The
1398874.1/12504.012 1 3
following procedure was followed to obtain 3-(tert-butyldimethylsilyloxy)-5- hydroxybenzaldehyde (9b). 3,5-dihydroxybenzaldehyde (1.1 g) in dimethylformamide (10 ml) was monosilylated using DIEA (1.9 ml, 1.4 equiv.) and the silyl chloride (1.2 g) with stirring for 3 hours. The oily product was separated by flash column chromatography (9:1 hexane:ethyl acetate) afford some disilylated product (0.7 g) and the desired monosilylated product as a colorless oil (0.8 g, 38.5%) that crystallized from ethanol: mp = 79.6-80°C; EIMS m/z 252 (M+), 195, 167, 58, 45; IR (KBr, cm"1) vmax 3211, 2930, 2859, 1672, 1591, 1332, 841; 1H-NMR δ 9.84
(IH, s, CHO), 6.99 (IH, dd, J= 2.0, 1.0 Hz), 6.91 (IH, dd, J= 2.0, 1.0 Hz), 6.64 (IH, t, J= 2.0
Hz), 6.00 (IH, bs, OH), 0.97 (9H, s, C(CH3)3), 0.21 (6H, s, Si(CH3)2); 13C-NMR (75.5 MHz) δ
192.4, 157.6, 157.4, 138.3, 114.4, 114.0, 109.1, 25.6, 18.2, -4.47. Anal. (Cι3H20O3Si) C, H
Also, 3-(tert-butyldimethylsilyloxy)-5-methoxybenzaldehyde (9c) was obtained in a like manner. To a solution of phenol 9b (0.7 g) in dichloromethane (10 ml) was added molecular sieves (4 A, 0.8 g), proton sponge (1.6 g, 2.5 eq.), and trimethyloxonium tetrafluoroborate (1.1 g, 2.5 eq), and the solution was stined for 15 hours. The solution was filtered, the sieves were rinsed with ethyl acetate and the solvent was removed from the combined filtrate in vacuo to yield a yellow oil. The oil was purified by flash column chromatography (10:1 hexane:ethyl acetate), yielding a colorless oil (0.6 g, 79%): EIMS m/z 266 (M+), 209, 181, 166, 89, 58, IR
(KBr, cm"1) vmax 2932, 2859, 1703, 1593, 1468, 1337, 1059, 839; Η-NMR δ 9.86 (IH, s, CHO), 7.00 (IH, d, J= 2.0 Hz), 6.92 (IH, d, J= 2.0 Hz), 6.63 (IH, t, J= 2.0 Hz), 3.81 (3H, s, OCH3),
0.97 (9H, s, C(CH3)3), 0.21 , (6H, Si(CH3)2); 13C-NMR (75.5 MHz) δ 191.8, 161.2, 157.3,
138.4, 114.5, 113.0, 106.6, 55.5, 25.6, 18.2, -4.5. Anal. (CHH22O3Si) C,H.
In addition, 3-(tert-butyldimethylsilyloxy)-5,4'-dimethoxy-stilbene (14e and 14f) was obtained in a similar fashion. Reacting phosphonium bromide 8 (1.71 g) with aldehyde 9c (1.0
1398874.1/12504.012 \_\
g) led to stilbenes 14e and 14f (0.75 g, 55% total yield). (Z)-isomer (14e): EIMS m/z 370 (M+),
313, 298, 156, 89; IR (KBr, cm"1) vmax 2955, 2859, 1588, 1510, 1433, 1252, 1159, 1034, 839,
679; 1H-NMR δ 7.21 (2H, d, J= 9.0 Hz), 6.77 (2H, d, J= 9.0 Hz), 6.52 (IH, d, J= 12.0 Hz),
6.45 (IH, s) 6.43 (IH d, J= 12.0 Hz), 6.36 (IH, d, J= 2.1 Hz), 6.27 (IH, t, J= 2.1 Hz), 3.78 (3H, s, OCH3), 3.67 (3H, s, OCH3), 0.95 (9H, s, C(CH3)3), 0.11 (6H, s, Si(CH3)2); 13C-NMR
(75.5 MHz) (75.5 MHz) δ 160.6, 158.8, 156.7, 139.4, 130.3, 128.8, 127.5, 126.3, 113.6,110.9,
105.4, 55.2, 25.3, 14.1, -4.5. Anal. (C22H30O3Si) C,H. (E)-isomer (14f): EIMS m/z 370 (M+),
313, 298, 156, 89; IR (KBr, cm"1) vmax 2955, 2859, 1588, 1510, 1433, 1252, 1159, 1034, 941,
839; 1H-NMR δ 7.45 (2H, d, J= 8.7 Hz), 7.01 (IH, d, J= 15.9 Hz), 6.90 (2H, d, J= 8.7 Hz),
6.87 (IH, d, J= 15.9 Hz), 6.66 (IH, s), 6.58 (IH, s), 6.31 (IH, t, J= 2.1 Hz), 3.83 (3H, s, OCH3),
3.81 (3H, s, OCH3), 1.00 (9H, s, C(CH3)3), 0.23 (6H, s, Si(CH3)2); 13C-NMR (75.5 MHz) δ 160.8, 159.4, 156.9, 139.6, 130.0, 128.5, 127.8, 126.6, 114.1, 110.9, 104.8, 55.3, 25.7, 14.1, - 4.4. Anal. (C22H30O3Si) C, H.
A similar process was followed to obtain 3-hydroxy-4',5-dimethoxystilbene (14g and 14h). The preceding stilbene (0.75 g) isomeric mixture was deprotected and the products separated by gravity column chromatography (9:1 hexane:ethyl acetate). As usual the cis- stilbene (0.25 g) eluted first followed by the trans-isomer (0.26 g, 99% total yield): (_Z)-isomer
(14g): EIMS m/z 256 (M+), 225, 181, 152, 115; IR (KBr, cm"1) vmax 3407, 3005, 2938, 2837,
1607, 1511, 1456, 1300, 1254, 1154 1057, ' H-NMR δ 7.20 (2H, d, J= 9.0 Hz), 6.77 (2H, d, J=
9.0 Hz), 6.52 (IH, d, J= 12.0 Hz), 6.42 (IH, s), 6.40 (IH d, J= 12.0 Hz), 6.33 (IH, d, J= 2.1 Hz), 6.27 (IH, t, J= 2.1 Hz), 3.79 (3H, s, OCH3), 3.67 (3H, s, OCH3). Anal. (Cι6Hι6O3) C,H.
(EHsomer (14h): EIMS m/z 256 (M+), 225, 181, 152, 115; IR (KBr, cm"1) vmax 3405, 2936,
2837, 1593, 1510, 1456, 1252, 1150,1057; and 1H-NMR δ 7.44 (2H, d, J= 8.7 Hz), 7.02 (IH, d,
1398874.1/12504.012 15
J= 15.9 Hz), 6.90 (2H, d, J= 8.7 Hz), 6.86 (IH, d, J= 15.9 Hz), 6.63 (1 H, t, J= 2.1 Hz), 6.58 (1 H, t, J= 2.1 Hz), 6.31 (1 H, t, J= 2.1 Hz), 3.83 (3H, s, OCH3) 3.82 (3H, s, OCH3).
In a like manner 3,5-di(tert-butyldimethylsilyloxy)-4'-methoxy-stilbene (14i and 14j) was obtained. Intermediate 9a and 3 served as starting material for preparing stilbene 14i (1.73 g)
and 14j (0.19 g). (Z)-isomer (14i); EIMS m/z 470 (M+), 455, 413, 147, 73; IR (KBr, cm"1) vmax
2955, 2859, 1582, 1510, 1437, 1331, 1254, 1165, 1031, 678; 1H-NMR δ 7.17 (2H, d, J= 8.1
Hz), 6.75 (2H, d, J= 8.1 Hz), 6.49 (1 H, d, J= 12.0 Hz), 6.39 (IH, d, J= 12.0 Hz), 6.35 (2H, d, J = 2.4 Hz), 6.19 (IH, t, J= 2.4 Hz), 3.77 (3H, s, OCH3), 0.93 (18H, s, C(CH3)3 x 2), 0.10 (12H, s, Si(CH3)2 x 2). Anal. (C25H42O3Si2) C.H. (E)-isomer (14j); EIMS m/z 470 (M+), 455, 413, 147, 73; IR (KBr, cm"1) vmax 2955, 2859, 1582, 1510, 1437, 1331, 1254, 1165, 1031, 980; Η-NMR δ 7.44 (2H, d, -7= 8.1 Hz), 6.97 (IH, d, J= 16.2 Hz), 6.89 (2H, d, J= 8.1 Hz), 6.83 (1 H, d, J= 16.2 Hz), 6.59 (2H, d, J= 2.1 Hz), 6.24 (114, t, J= 2.1 Hz), 3.83 (3H, s, OCH3), 1.00 (18H, s, C(CH3)3 x 2), 0.22 (12H, s, Si(CH3)3 x 2).
The preceding silyloxy protected stilbene isomers (14i and j) were deprotected to yield 3,5-dihydroxy-4'-methoxy-stilbene (14k and 1) 0.60 g and 0.05 g respectively. (Z)-isomer (14k);
EIMS m/z 242 (M+), 226, 211, 194, 181, 152, 137, IR (KBr, cm"1) vmax 3356, 3009, 2971, 2837,
1605, 1510, 1254, 1154, 1005, 677; Η-NMR δ 7.20 (2H, d, J= 8.7), 6.77 (2H, d, J= 8.7 Hz),
6.50 (IH, d, J= 12.0 Hz) 6.36 (IH, d, J= 12.0 Hz), 6.32 (2H, d, J= 2.1 Hz), 6.22 (IH, t, J= 2.1 Hz), 4.89 (2H, bs, OH x2), 3.77 (3H, s, OCH3). Anal. (Cι5Hι4O3) C,H. E-Isomer (141); EIMS
m/z 242, (M+), 226, 211, 194, 181, 152,137; IR (KBr, cm"1) vmax 3356, 3009, 2971, 2837, 1605,
1510, 1254, 1154, 1005, 974; Η-NMR δ 7.43 (2H, d, J= 8.1 Hz), 7.01, (IH, d, J = 15.9 Hz),
6.90 (2H, d, J= 8.1 Hz), 6.83 (IH, d, J= 15.9 Hz), 6.56 (2H, d, J= 2.4 Hz), 6.25 (IH, t, J= 2.4 Hz), 4.70 (2H, bs, OH x 2), 3.83 (3H, s, OCH3).
1398874.1/12504.012 tfj
Then (Z)-3,5-dimethoxy-4 -[O-bis(benzyl)phosphoryl]-stilbene (14m) was obtained as follows. A mixture of phenol 14c (3.9 g) and N,N-dimcthyla inopyridinc (0.2 g) in anhydrous acetonitrile (30 ml) was cooled to -10°C, and carbon tetrachloride (7.3 ml, 5 equiv.) and DIEA (5.5 ml, 2.1 equiv.) were added. The mixture was stined at -10°C for 30 minutes under argon, dibenzylphosphite (5.0 ml, 1.5 equiv.) was added, .and the solution was stined for 12 hours and then poured into 0.5 M monobasic potassium phosphate. The mixture was extracted with ethyl acetate and removal of solvent in vacuo from the organic phase yielded a tan oil. This was subjected to column chromatography (4:1 hexane:ethyl acetate), and the phosphate ester was recovered as a tan oil (6.6 g, 85%): EIMS m/z 516 (M+), 425, 334, 319, 255, 227, 91; IR (KBr, cm"1) vmax 3443, 3007, 2959, 2837, 1591, 1505, 1456, 1289, 1208, 1155, 1015, 953: 1H-ΝMR δ 7.32 (10H, m, AR-H), 7.19 (2H d, J= 8.4 Hz), 7.01 (2H, d, J= 8.4 Hz), 6.52 (2H, s, H,a>,.a), 6.36 (2H, d, J= 2.0 Hz), 6.31 (IH, t, J= 2.0 Hz), 5.11 (2H, s, Bn), 5.08 (2H, s, Bn), 3.62 (6H, s, OCH3 x 2); 13C-NMR (75.5 MHz) δ 160.6, 149.5, 149.5, 138.8,135.4, 135.4, 134.2, 130.4, 130.3, 129.4, 128.6, 128.6, 128.0, 127.0, 119.8, 119.7, 106.6, 99.8, 70.0, 69.9, 55.2. Anal. (C30H29O6P) C, H, P.
Sodium Resverastatin Phosphate (14n) was obtained as described below. To a solution of the dibenzyl phosphate (14m, 2.62 g) in anhydrous dichloromethane (15 ml) at 0°C was added bromotrimethylsilane (1.40 ml, 2.1 equiv.), and the mixture was stined for 2 hours. Water (10 ml) was added, the solution was stined for 1 hour and then washed with ethyl acetate, and the aqueous phase was freeze-dried to a white solid. To a solution of the solid in ethanol (30 ml) was added sodium methoxide (0.57 g), and the suspension was stined for 12 hours. Solvent was removed in vacuo and the resulting tan oil was dissolved in water. The solution was washed with ethyl acetate and then freeze-dried to afford 1.88 g of colorless solid (98%): HRFAB m/z;
1398874.1/12504.012 17
IR (KBr, cm"1) vmax 3385, 2999, 2938, 2834, 1601, 1508, 1366, 1155, 1063, 683; 1H-NMR δ
6.93 (2H, d, J= 8.4 Hz), 6.85 (2H, d, J= 8.4 Hz), 6.29 (1 H, d, J= 12.4 Hz), 6.17 (2H, s, H2>6),
6.15 (IH, d, J= 12.4 Hz), 6.09 (IH, s, H4),3.34 (6H, s, OCH3 x 2); 13C-NMR (75.5 MHz) δ
171.1, 160.1, 139.9, 131.8, 130.8, 130.0, 129.0, 120.3, 107.3, 99.7, 55.6.
The following general procedure was used for benzhydrol formation. To the bromide (1- 10 mmol) in anhydrous tetrahydrofuran (5-35 ml) at -78°C was added n-butyllithium (2.5 M, 1.1 equiv.) and the resulting solution stined under argon for 15 minutes. A solution of aldehyde (1.0 equiv.) in tetrahydrofuran was added dropwise over 30 minutes and the mixture stined for 6 hours. The solution was poured into water and extracted with ethyl acetate. The organic phase was washed with water and removal of the solvent in vacuo afforded an oil that was purified by flash column chromatography (9:1 hexane-ethyl acetate).
Reacting 4-bromoanisole (2.3 g) and 3,5-dimethoxybenzaldehyde (2.1 g) led to 15a (2.7 g, 80.9%) as a colorless oil: EIMS m/z 274 (M+) 257, 243, 227, 165, 139, 135, 109, 77; IR
(KBr, cm"1) vmax 3451, 3001, 2940, 2837, 1597, 1248, 1172, 1034; 1H-NMR δ 7.28 (2H, d, J=
8.8 Hz), 6.85 (2H, d, J= 8.8 Hz), 6.53 (2H, d, J= 2.0 Hz), 6.35 (IH, t, J= 2.0 Hz), 5.72 (IH, d, J
= 2.8 Hz), 3.78 (3H, s, OCH3), 3.76 (3H, s, OCH3); 13C-NMR (75.5 MHz) δ 160.9, 159.1, 146.5,
135.9, 127.9, 113.9, 104.4, 99.3, 75.8, 55.3, 55.3. Anal. (C.6Hι8O4) C, H.
The following general procedure was followed for benzophenone formation. To a solution of the benzhydrol (1-10 mmol) in dichloromethane (5-35 ml) was added pyridinium dichromate (2.0 equiv.) and molecular sieves (4 A activated powder, same weight as PDC), and the resulting suspension was stined under argon for 24 hours. The reaction mixture was filtered through celite and the solvent removed in vacuo to yield a brown oil. The oil was subjected to
1398874.1/12504.012 l g
gravity column chromatography (4:1 hexane-ethyl acetate) to yield the desired product in 75-
90% yield.
Further, 3,4',5-trimethoxybenzophenone (16a) was obtained. Alcohol 15a (1.1 g) provided a solid (0.8 g, 77.7%) that recrystallized from methanol in colorless needles: m.p. = 90.3-91.6°C (lit.21 m.p. = 97-98°C); EIMS m/z 272 (M+), 257, 241, 229, 165, 135, 92, 77; IR (KBr.cm"1) vmax 3071, 2967, 2841, 1645, 1588, 1263, 1065; 1H-NMR δ 7.84 (2H, d, J= 9.0 Hz),
6.95 (2H, d, J= 9.0 Hz), 6.87 (2H, d, J= 2.0 Hz), 6.65 (IH, t, J= 2.0 Hz), 3.88 (3H, s, OCH3),
3.82 (3H, s, OCH3); 13C-NMR (75.5 MHz) δ 195.2, 163.3, 160.5, 140.2, 132.6, 130.1, 113.6,
107.6, 104.2, 55.6, Anal. (Cι6Hι6O4) C, H.
Then l-bromo-4-O-(/ert-butyldimethylsilyloxy)benzene (17) was obtained. First, 4-
bromophenol (4.15 g) was dissolved in anhydrous dichloromethane (40 ml), then imidazole (1.63 g) and tert-butyldimethylsilyl chloride (3.61 g) were added. The cream suspension was stined under argon for 12 hours and the reaction was terminated with addition of water. The mixture was extracted with ethyl acetate. The organic phase was washed with water and the solvent was removed in vacuo to afford a yellow oil that was subjected to flash column chromatography (9:1 hexane:ethyl acetate) to yield a colorless oil (87%, 6.0g): EIMS m/z 274 (M+), 257, 243, 227,
165, 139, 135, 109, 77; IR (KBr, cm"1) vmax 2957, 2859, 1588, 1487, 1458, 910, 839; 1H-NMR δ
7.32 (2H, d, J= 8.7 Hz), 6.71 (2H, d, J=8.7 Hz), 0.97 (9H, s, C(CH3)3), 0.18 (6H, s, Si(CH3)2). Anal (Cι2H]9BrOSi) C, H.
Protected bromophenol 17 (3.2 g) and 3,5-dimethoxybenzaldehyde (1.8 g) afforded 15b as a colorless oil (3.4 g, 83%): EIMS m/z 374 (M+), 317, 167, 151, 139; IR (KBr, cm"1 vmax
3420, 2957, 2859, 1607, 1260, 1155, 1063, 839; 1H-NMR δ 7.21 (2H, d, J= 8.4 Hz), 6.80 (2H, d, J= 8.4 Hz), 6.53 (2H, d, J= 2.0 Hz), 6.36 (IH, t, J= 2.0 Hz), 5.67 (IH, s), 3.75 (6H, s, OCH3
1398874.1/12504.012 19
x 2), 0.99 (9H, s, C(CH3)3), 0.20 (6H, s, Si(CH3)2); 13C-NMR (75.5 MHz) δ 160.7, 155.0, 146.5,
136.4, 127.8, 119.9, 104.4, 99.2, 75.7, 55.2, 25.6, 18.1, -4.5. Anal. (C2ιH30O4Si) C, H.
Alcohol 15b (0.12g) was deprotected with TBAF as for the stilbenes above to provide 4'- Hydroxy-3,5-dimethoxybenzhydrol 15c as a colorless oil (0.03 g, 42%): EIMS m/z 260 (M+),
243, 165, 139, 121, 95; IR (KBr, cm"1) vmax 3362, 2932, 2859, 1599, 1256, 1155, 1067; 1H-NMR
δ 7.16 (2H, d, J= 8.4 Hz), 6.72 (2H, d, J= 8.4 Hz), 6.52 (2H, d, J= 2.4 Hz), 6.34 (IH, t, J= 2.4
Hz), 5.66 (IH, s), 3.73 (6H, s, OCH3 x 2); 13C-NMR (75.5 MHz) δ 160.6, 155.4, 146.3, 135.3, 128.0, 115.3, 104.4, 99.2, 75.8, 55.3. Anal. (Cι5H,6O4) C, H.
Alcohol 15b (0.58 g) led to 4'-(ter/-butyldimethylsilyloxy)-3,5-dimethoxybenzophenone 16b as a colorless oil (0.46 g, 80%): EIMS m/z 372 (M+), 315, 165, 157, 137, 28; IR (KBr, cm"1)
vmax 2957, 2859, 1657, 1260, 1067, 910, 841; Η-NMR δ 7.78 (2H, d, J= 9.2 Hz), 6.89 (2H, d, J
= 9.2 Hz), 6.87 (2H, t, J= 2.0 Hz), 6.63 (IH, t, J= 2.0 Hz), 3.80 (6H, s, OCH3 x 2), 0.98 (9H, s,
C(CH3)3), 0.23 (6H, s, Si(CH3)2); 13C-NMR (75.5 MHz) δ 195.0, 160.3, 159.8, 140.0, 132.3,
130.5, 119.6, 107.5, 104.1, 55.5, 25.6, 18.3, -4.3. Anal. (C2.H28O4Si) C;H.
The general procedure for benzophenone deprotection with TBAF is set forth below. To a solution of the protected phenol (0.3-3.5 mmol) in anhydrous tetrahydrofuran (5-25 ml) was added tetrabutylammonium fluoride (1 M, 1.0 equiv. per TBDMS), and the pale yellow solution was stined for 45 minutes. The mixture was poured into water and extracted with ethyl acetate. Removal of the solvent in vacuo from the organic phase afforded a tan oil that was subjected to gravity column chromatography (9:1 hexane:ethyl acetate) to afford the product (70-93% yield).
Protected benzophenone 16b (0.71 g) led to 16c as a white solid (0.35 g, 72%): EIMS
m/z 258 (M+), 243, 227, 199, 165, 121, 45; IR (KBr, cm"1) vmax 3424, 2940, 1640, 1591, 1454,
1206, 1157, 1065; 1H-NMR δ 7.68 (2H, d, J= 8.8 Hz), 6.80 (2H, d, J= 8.8 Hz), 6.75 (2H, d, J=
1398874.1/12504.012 20
2.0 Hz), 6.53 (IH, t, J= 2.0 Hz), 3.70 (6H, s, OCH3 x 2);13C-NMR (75.5 MHz) δ 196.0, 162.3,
160.4, 140.2,133.1, 128.6, 115.6, 107.5, 104.2, 55.5. Anal. (Cι5H,4O4) C, H.
Combining 4-bromoanisole (0.43 g) and aldehyde 9a (0.76 g) provided 3,5-di-(tert- butyldimethylsilyloxy)-4'-methoxybenzhydrol 15d as a faint yellow oil (0.80 g, 82%): EIMS
m/z 474 (M+), 459, 417, 361, 343, 73; IR (KBr, cm"1) vmax 3420, 2932, 2859, 2361, 1591, 1451,
1252, 1163, 1026, 833; 1H-NMR δ 7.29 (2H, d, J= 9.04 Hz), 6.89 (2H, d, J= 9.0 Hz), 6.52 (2H,
d, J= 2.0 Hz), 6.28 (IH, t, J= 2.0 Hz), 5.70 (IH, s), 3.83 (3H, s, OCH3), 1.00 (18H, s, C(CH3)3 x
2), 0.20 (12H s, Si(CH3)2 x 2); 13C-NMR (75.5 MHz) δ 159.0, 156.5, 146.1, 136.0, 127.9, 113.7,
111.5, 111.0, 75.5, 55.3, 25.7, 18.2, -4.4. Anal. (C26H_,2O4Si2) C, H.
Alcohol 15d (0.72 g) provided 3,5-di-(tert-butyldimethylsilyloxy)-4'- methoxybenzophenone 16d as a colorless oil (0.64 g, 90%): EIMS m/z 472 (M+), 457, 415, 359,
135, 73, IR (KBr, cm"1) vmax 2957, 2932, 2859, 1657, 1586, 1437, 1339, 1254, 1169, 831; Η-
NMR δ 7.82 (2H, d, J= 9.0 Hz), 6.94 (2H, d, J= 9.0 Hz), 6.80 (2H, d, J= 1.5 Hz), 6.52 (IH, t, J
= 1.5 Hz), 3.88 (3H, s, OCH3), 0.97 (18H, s, C(CH3)3 x 2), 0.19 (12H, s, Si(CH3)2 x 2); 13C-
NMR (75.5 MHz) δ 195.0, 163.2, 156.3, 140.1, 132.5, 130.2, 115.6, 114.7, 113.5, 55.5, 25.7,
18.2, -4.4. Anal. (C26H40O4Si2) C, H.
Protected benzophenone 16d (0.54 g) led to 16e as a white solid (0.36 g, 93%): EIMS
m/z 244 (M+), 227, 135, 107, 92; IR (KBr, cm"1) vmax 3300, 2972, 2841, 2361, 1692, 1591, 1451,
1350, 1263,1171,1030; 1H-NMR δ 8.60 (2H, bs, OH x 2), 7.80 (2H, d, J= 9.0 Hz), 7.06 (2H, d, J
= 9.0 Hz), 6.69 (2H, d, J= 2.5 Hz), 6.59 (IH, t, J= 2.5 Hz), 3.91 (3H, s, OCH3); 13C-NMR (75.5
MHz) δ 195.4, 164.6, 159.7, 141.8, 133.4, 131.5, 114.8, 109.3, 107.2, 56.4. Anal. (C!4HI2O ) C, H.
1398874.1/12504.012 21
Protected bromophenol 17 (0.49 g) and aldehyde 9a (0.62 g) afforded 15e as a faint
yellow oil (0.76 g, 78%): EIMS m/z 574 (M+), 559, 517, 461, 443, 73; IR (KBr, cm"1) vmax 3420,
2932, 2859, 2361, 1591, 1451, 1252, 1163, 1026, 833; 1H-NMR δ 7.18 (2H, d, J= 8.5 Hz), 6.79
(2H, d, J= 8.5 Hz), 6.48 (2H, d, J= 2.0 Hz), 6.25 (IH, t, J= 2.0 Hz), 5.63 (IH, s, CH), 0.99 (9H, s, C(CH3)3), 0.97 (18H, s, C(CH3)3 x 2), 0.19 (6H, s, Si(CH3)2 x 2), 0.17 (12H, s, Si(CH3)2 x2);
13C-NMR (75.5 MHz) δ 156.4, 155.0, 146.2, 136.7, 127.9, 119.9, 111.6, 111.0, 75.4, 25.7, 18.2, -
4.4, -4.5. Anal. (C3ιH54O4Si3) C, H.
Alcohol 15e (0.50 g) led to 16f as a colorless oil (0.44 g, 89%): EIMS m/z 572 (M+),
515, 459, 323, 193, 73; IR (KBr, cm"1) vmax 2932, 2861, 1661, 1589, 1437, 1339, 1256, 1167,
831; lH-NMR δ 7.74 (2H, d, J= 8.5 Hz), 6.88 (2H, d, J= 8.5 Hz), 6.80 (2H, d, J= 2.5 Hz), 6.52
(IH, t, J= 2.5 Hz), 0.99 (9H, s, C(CH3)3), 0.97 (18H, s, C(CH3)3 x 2), 0.24 (6H, s, Si(CH3)2),
0.19 (12H, s, Si(CH3)2 x 2); 13C-NMR (75.5 MHz) δ 195.2, 159.9, 156.3, 140.0, 132.4, 130.7,
119.7, 115.7, 114.7, 25.7, 25.6, 18.3, 18.2, -4.4. Anal. (C3ιH52O4Si3) C,H.
Protected benzophenone 16f (0.42 g) led to 3,4',5-trihydroxybenzophenone 16g as a
white solid (0.12 g, 73%): EIMS m/z 230 (M+, 137, 121, 93, 65, 28; IR (KBr, cm"1) vmax 3300,
2974, 1692, 1593, 1346, 1260, 1167; 1H-NMR δ 7.73 (2H, d, J= 8.5 Hz), 6.95 (2H, d,.J= 8.5
Hz), 6.68 (2H, d, J= 2.0 Hz), 6.57 (IH, t, J= 2.0 Hz); 13C-NMR (75.5 MHz) δ 195.0, 162.4,
159.2, 141.6, 133.3, 130.2, 115.9, 108.8, 106.7. Anal. (Cι3Hι0O4) C, H.
Protected bromophenol 17 (1.07 g) and aldehyde 9c (0.99 g) provided 15f as a faint
yellow oil (1.19 g, 67%): EIMS m/z 474 (M+), 459, 417, 361, 343, 73; IR (KBr, cm"1) vmax 3397,
2932, 2859, 1595, 1508, 1256, 1159, 839; Η-NMR δ 7.19 (2H, d, J= 8.4 Hz), 6.78 (2H, d, J= 8.4 Hz), 6.55 (IH, s), 6.42 (IH, s), 6.29 (IH, s), 5.67 (IH, s, CH), 3.74 (3H, s, OCH3), 0.96 (9H, s, C(CH3)3), 0.95 (9H, s, C(CH3)3), 0.17 (6H, s, Si(CH3)2), 0.15 (6H, s, Si(CH3)2); 13C-NMR
1398874.1/12504.012 22
(75.5 MHz) δ 160.5, 156.6, 155.0, 146.2, 136.4, 127.8, 119.9, 110.8, 105.1, 105.0, 75.7, 55.3,
25.7,18.3), -4.3. Anal. (C26H42O Si2) C, H.
Alcohol 15f (0.91 g) led to 16h as a colorless oil (0.71 g, 78%): EIMS m/z 472 (M+),
415, 223, 193, 179, 73; IR (KBr, cm"1) vmax 2932, 2859, 1659, 1595, 1507, 1258, 1163, 839; 1H-
NMR δ 7.76 (2H, d, J= 8.8 Hz), 6.90 (IH, t, J= 2.4 Hz), 6.88 (2H, d, J= 8.8 Hz), 6.77 (IH, t, J
= 2.4 Hz), 6.58 (IH, t, J= 2.4 Hz), 3.80 (3H, s, OCH3), 0.99 (9H, s, C(CH3)3), 0.97 (9H, s,
C(CH3)3), 0.24 (6H, s, Si(CH3)2), 0.20 (6H, s, Si(CH3)2); 13C-NMR (75.5 MHz) δ 195.0, 160.3,
159.8, 156.3, 140.0, 132.3, 130.6, 119.6, 114.2, 110.1, 107.6, 55.5, 25.7, 25.7, 18.3, 18.3, -4.3.
Anal. (C26H4oO4Si2) C, H.
Protected benzophenone 16h (0.61 g) led to 3,4'-dihydroxy-5-methoxybenzophenone 16i as a white solid (0.26 g, 82%): mp 179-180°C; EIMS m/z 244 (M+), 229, 213, 151, 121, 93; IR (KBr, cm"1) vmax 3333, 2961, 2841, 1690, 1589, 1435, 1346, 1165, 1059, 849; Η-NMR δ 9.21 IH bs, OH), 8.66 (IH, bs, OH), 7.75 (2H, d, J= 9.0 Hz), 6.96 (2H, d, J= 9.0 Hz), 6.77 (2H, t, J = 2.0 Hz), 6.74 (IH, t, J= 2.0 Hz), 6.63 (IH, t, J= 2.0 Hz), 3.80 (3H, s, OCH3); 13C-NMR (75.5 MHz) δ 195.0, 162.6, 161.8, 159.2, 141.6, 133.4, 130.1, 116.0, 109.9, 107.0, 105.50, 55.8. Anal.
(Cι4H]2O4) C, H.
Combining 4-bromoanisole (0.59 g) and aldehyde 9c (0.82 g) provided compound 15g as a faint yellow oil (0,59 g, 52%): EIMS m/z 374 (M+), 359, 317, 299, 243, 75; IR (KBr, cm"1)
vmax 3418, 2932, 2859, 1595, 1462, 1250, 1157, 1036, 837; 1H-NMR δ 7.30 (2H, d, J= 8.4 Hz), 6.89 (2H, d, J= 8.4 Hz), 6.58 (IH, s), 6.49 (IH, s), 6.32 (IH, s), 5.72 (IH, s, CH), 3.82 (3H, s, OCH3), 3.77 (3H, s OCH3), 0.99 (9H, s, C(CH3)3), 0.20 (6H, s, Si(CH3)2); 13C-NMR (75.5 MHz)
δ 160.5, 158.9, 156.6, 146.2, 135.9, 127.8, 113.8, 110.7, 105.1, 104.9, 75.6, 55.3, 25.8, 18.3, - 4.3. Anal. (C2ιH30O4Si) C,H.
1398874.1/12504.012 23
Alcohol 15g (0.54 g) led to colorless oil 3'-(tert-butyldimethylsilyloxy)-4',5- dimethoxybenzophenone 16j (0.41 g, 76%): EIMS m/z 372 (M+), 315, 272, 135; IR (KBr, cm"1) vmax 2932, 2859, 1657, 1593, 1454, 1429, 1339, 1254, 1161, 1034, 839; Η-NMR δ 7.83 (2H, d, J= 8.8 Hz), 6.95 (2H, d, J= 8.8 Hz), 6.89 (IH, t, J= 1.2 Hz), 6.77 (IH, t, J= 1.6 Hz), 6.58 (IH, t, J= 2.2 Hz), 3.88 (3H, s, OCH3), 3.80 (3H, s, OCH3), 0.97 (9H, s, C(CH3)3), 0.20 (6H, s,
Si(CH3)2); 13C-NMR (75.5 MHz) δ 194.9, 163.1, 160.4, 156.3, 140.1, 132.5, 130.0, 114.2, 113.4,
110.1, 107.6, 55.6, 55.5, 25.7, 18.1, -4.3. Anal. (C2ιH28O4Si) C,H.
Protected benzophenone 16j (0.37 g) led to 4',5-dimethoxy-3-hydroxybenzophenone 16k
as a colorless solid (0.18 g, 70%): EIMS m/z 258 (M+), 227, 135, 92, 77; IR (KBr, cm"1) vmax
3354, 3005, 2938, 2841, 1692, 1636, 1593, 1433, 1346, 1256, 1171, 1030; Η-NMR δ 8.67 (IH,
bs, OH), 7.80 (2H, dd, J= 6.8, 2.0 Hz), 7.05 (2H, dd, J= 6.8, 2.0 Hz), 6.77 (IH, dd, J= 2.0, 1.6 Hz), 6.74 (IH, dd, J= 2.4, 1.2 Hz), 6.64 (IH, t, J= 2.4 Hz), 3.90 (3H, s, OCH3), 3.80 (3H, s,
OCH3); 13C-NMR (75.5 MHz) δ 194.6, 164.0, 161.5, 159.0, 141.1, 132.8, 130.8, 114.3, 109.7,
106.9, 105.4, 55.9, 55.7. Anal. (C15Hι4O4) C, H.
The following results lead to some observations. Because of the interesting biological properties of resveratrol (1), combined with the remarkable in vivo anticancer activity of combretastatin A-4 (2a) and its sodium phosphate prodrug (2b), a series of resveratrol structural modifications were investigated as an extension of applicant's combretastatin and phenstatin (2c) SAR research. (Ndayikengurukiye, H., et al., Alkoxylated p-phenylenevinylene Oligomers: Synthesis and Spectroscopic and Electrochemical Properties, Tetrahedron 1997, 53, 13811- 13828.) Suitable application of the experimental procedures already developed for synthesis of combretastatin A-4 and its prodrug derivatives was extended to obtaining the cis and trans stilbenes as well as the benzophenones. (Pettit, G. R., et al., Antineoplastic agents 291. Isolation
1398874.1/12504.012 24
and synthesis of Combretastatin A04, A-5, and A-6, J. Med. Chem. 1995, 38, 1666-1672; Pettit, G. R., et al., Antineoplastic agents 443. Synthesis of the Cancer Cell Growth Inhibitor Hydocyphenstatin and its Sodium Diphosphate Prodrug, J. Med. Chem. 2000, 43, 2731-2727.)
The cytotoxicity data from the resveratrol stilbenes was determined. The cΛs-isomer of resveratrol (lb) exhibited slightly less inhibitory effects on the cancer cell lines tested than did the tranj-isomer. The trimethoxy stilbenes 4a,b are between 10-100 fold more active against tumor cell lines than the parent compound resveratrol (1), with compound 4a (the α's-stilbene) far more active than 4b.
Demethylation at any position yielded much less cytotoxic compounds than 4a, but the cw-stilbenes 14c, 14g and 14k all retained anticancer activity comparable to that of resveratrol. The conesponding traws-isomers 14d, 14h and 141 were all slightly less active than their cis counterparts.
Previous work by applicant had found that phenstatin (2c) retained most of the cytotoxic properties of combretastatin A-4 (2a); this suggested that the properties of compound 16a, as well as additional benzophenones might possibly be worthy of further investigation. (Pettit, G. R., et al., Antineoplastic Agents. 379. Synthesis of Phenstatin Phosphate, J. Med. Chem. 1998, 41, 1688-1695.) While the cytotoxic properties of most of these compounds were quite similar to those of the stilbene derivatives of resveratrol the trimethoxy derivative was again the most potent of the series. However, it was 10- 100-fold less active than compound 4a, the analogous cw-stilbene.
General conclusions arising from the structure-activity relationship study of resveratrol based on cytotoxic effects on P-388 and human tumor cell lines can be summarized as: 3,4',5- OCH3»resveratrol,4'-OH,prodrug,3-OH>3,5-OH,3,4'-OH»3,4',5-OH. The trimethoxy
1398874.1/12504.012 25
derivatives (4a,b,16a) were all superior in activity to resveratrol (1) as well as the remaining variations. Resveratrol (1), however, was comparable in activity to several of the other cis- stilbenes described here, including the 4'-hydroxy (14g) and the 3-hydroxy (14c) -derivatives.
For this reason the synthesis of the prodrug of the 4'-hydroxystilbene 14c and the 3- hydroxystilbene 14g was attempted. The synthesized prodrug 14n was essentially identical to 14c in its effects on the growth of cancer cells. From the known antimitotic activity of combretastatin A-4 (2a) and phenstatin (2c) and their potent interactions with tubulin, it seemed possible that the most cytotoxic compounds prepared in the cunent series would also inhibit this important cellular protein.
Several of the newly synthesized compounds were therefore examined for inhibitory effects on tubulin assembly, in a direct comparison with 2a and 2c. Compound 4a proved to be more inhibitory than 2a, while, in contrast, 16a was somewhat less potent than 2c. Resveratrol (1) was inactive as an inhibitor of tubulin assembly. Compound 14c, representing demethylation at position 3 of 4a, was 16-fold less active than 4a.
Combretastatin A-4 (2a) binds in the colchicine site of tubulin and is exceptionally potent as an inhibitor of the binding of radiolabeled colchicine to tubulin. (Lin, C. M., et al., Antimitotic natural products Combretastatin A-4 and Combretastatin A-2: Studies on the Mechanism of Their Inhibition of the Binding of Colchicine to Tubulin, Biochem. 1989, 28, 6984-6991.) The two new active compounds, 4a and 4c, were compared to 2a and phenstatin (2c) for their effects on colchicine binding to tubulin. Combretastatin A-4 (2a) displayed its usual potency, inhibiting colchicine binding by 98% when the two drugs were present in equimolar (5 μM) concentrations and by 91% when 2a was present at 2 μM (the tubulin
concentration in these experiments was 1.0 μM).
1398874.1/12504.012 26
Compound 4a was essentially equivalent to 2a as an inhibitor of colchicine binding. Phenstatin (2c), despite its greater inhibition of polymerization, was less potent than combretastatin A-4 (2a) as an inhibitor of colchicine binding, while 16a had the least activity in both assays. The reasons for these discrepancies are at present unknown but do not appear to derive from salt or temperature differences in the reaction condition.
There is also some indication that Resveratrol (1) contained in the roots of Polygonum cuspidatum has apparently been used in Chinese and Japanese traditional medicine as a treatment for gononhea. (Kubo, M., et al., Shoyayugaku Zasshi 1981, 35, 58.) In the present study, its activity against the etiologic agent of gononhea, Neisseria gonorrhoeae, was demonstrated in broth microdilution assays (Table IV). Stilbene production has been conelated with the resistance of grape leaves to fungal infection. (Langcake, R., et al., The Relationship of Resveratrol Production to Infection of Grapevine Leaves by Botrytis cenerea, Vitis 1979 18:244- 253.) Most of the stilbenes evaluated for antimicrobial action had antifungal activity (Table IV). The dimethyl derivative of cw-resveratrol (14c), with both antibacterial and antifungal activities, was the most active of the stilbenes and benzophenones tested (Table IV). Further biological evaluation of such resveratrol structural modifications should include chemopreventive potential targets such as COX-1 and COX-2.
1398874.1/12504.012 27
Table I. Cytotoxicity Data of Resveralrol (1), Combrclastalin A-4 (2a), Resvcraslalin (14c), the Oisodium Resverastatin Prodnig (14n) and Related Stilbenes.
Leukemia I'uncrcas-a Drcust CNS lung-NSC Colon I'loslalc
Compound P388 UXl'C-3 MCF-7 SF-268 NCI-11460 KM20L2 DU-145
EDjoμg/mL GIjoμg/mL
4.49 j .3 3. 9 4.1 3 . - TTT — I7T-
TT 24.4 1S . S 14.8 5.0 13.2 22.0 10.2
Ta 3.0x10'* 0.39 - -1.0x10"'' 6.0X10-' 0.34 8.0x10'
Ta 2.62xl0'i 3.4xl0"3 - 4.4X10"1 2.8xl0"J 5.4x10'
TIT 2.77 3 .5X10'1 - 5.6x10-' 6.2x10'' 1.5
ΈΓ 2.95 12.6 3 . 0 2.2 2.8 11.9 2.3
T?Γ 4.87 6.5 2.3 4.3 2.7 3.4 2.7
-149- 3.82 3.3 - 1.5 7.2x10" 2.6 2.5 lAh.
31.5 12.7 - 10.3 11.2 13.1 6.0
______
2.75 14.1 12.7 15.6 6.4 17.7 10.6
______
28.9 6.3 3 .4 3.1 6 .8 3 .8 2.7
______
4.45 5.4 9.0 38.5 10.7 24.7 35.6
1 1"
2.81 6.6 7.3X10'1 1.9 3 .6 11.8 3.7
1398874.1/12504.012 28
Table II. Cytoloxicily Data ot Resveratrol (1), Phenstatin (2c) and Relaled Benzophenones and Benzhydrols.
Compound Leukemia Pαiicreas-a Breast CNS Lung-NSC Colon Pros
P388 BXPC-3 MCF-7 SH-268 NCI-H460 KM20L2 DU- l-D_0μg/nιL GIjoμg/mL
4.49 3.3 3.9 4.1 3.6 13.1
2C 3.3xl0'J - - 5.2x10"' 5.7xlO'J 4.0X10"1
Tϊn .
20.2 16.1 - 23.3 21.7 21.0 2
1.23 4.2X10'1 - 8.6x10"' 5.3x10" 4.2X10'1
_L5c_
>10 1.3 2.0 6.5x10" 2.3 5.3
.fir
24.8 4.0 2.2 3.8 3.0 3.6
______
17.8 21.2 21.7 24.5 16.6 24.5 1
>100 20.5 30.6 22.3 25.0 24.5 1
■ fit
26.2 21.7 26.8 26.4 12.1 31.6 ]
_!£--_
13.4 15.0 14.2 13.9 10.3 16.2 ]
1398874.1/12504.012 29
Table III. Interactions of stilbenes .and benzophenones with tubulin. Compound Inhibition of tubulin Inhibition of colchicine
Polymerization binding
IC50 (μM) ±SD % Inhibition
2μM inhibitor 5μM inhibitor
Resveratrol (1) >40
Combretastatin A-4 (2a) 2.0 ± 0.2 91 ± 3 98 ± 1
Phenstatin (2c) 1.1 ± 0.1 73 ± 1 85 ± 2
4a 1.8 ± 0.3 88 ± 1 95 ± 1
Resverastatin (14c) 29 ± 9
16a 2.6 ± 0.3 47 ± 5 69 ± 0.3
The tubulin polymerization assay was performed as previously described.24 The tubulin concentration was 10 μM, with varying drug concentrations, as required, to obtain IC5o values. Extent of assembly after 20 min at 30°C was the parameter measured. The colchicine binding assay was performed as earlier reported.27 The tubulin concentration was 1.0 μM, the [3H] colchicine concentration was 5.0 μM, and the potential inhibitor concentrations were as indicated. Binding of colchicine was measured following a 10 min incubation at 37°C.
04.012 30
Table IV. Antimicrobial activities of resveratrol (1) and related stilbenes and benzophenones
Minimum inhibitory concentration (μg/ml)
Microorganism 1 4a 14c 14h 14k 14u 15c 16a 16c 16e I6g 16! 16k
Cryptocaccus neofonnaiis * * 16 16 * 64 * * * * * * 64
Candida albicans * * 64 ♦ * * * * * * * * *
Staphylocυccus aureus * * 32 * * * * * * * * * *
Streptococcus pneumoniae * * 16 * * * 16 * 64 * 64 64 32-64
Enterococcus faecalis * * 32-64 * * * * * * * *
Microcυccus luteus * * 8 16-64 • 32-64 + * * *
Escherichla coll * * * * * * * + * * * *
Enterococcus faecalis * « * * * * * * ♦ * ♦ * *
Enterobacter cloacae * * * * * + • * •*• * * *
Slenυtrυphυmonas * * * * * + * * * * * * * nialtophilia
Neisseria gonorrhoeae 16-32 * 8 8 16 8-32 2-4 32 32-64 * * 32 16-32
\ no inhibition at 64 μg/ml
4.1/12504.012 31
Claims
What is claimed is: 1. A resveratrol derivative having the formula:
2. A resveratrol derivative having the formula:
wherein R4 = R5 = -OCH3 and R^ = -OH.
3. A resveratrol derivative having the formula:
R*. wherein R7 = R8 = -OH and R9 = -OCH3.
1398874.1/12504.012 32
4. A resveratrol derivative having the formula:
selected from the group consisting of compounds wherein: a) Rio = Ri i = -OCH3 and Ri2 = -O(PO)(OBn)2; and b) R10 = Rn = -OCH3 and Ri2 = -O(PO)(ONa)2.
5. A method for synthesizing the resveratrol derivative of claim 1 wherein Ri = R2 = R3 -OCH , comprising reacting phosphonium bromide and 3,5-dimethylbenzaldehyde.
6. A method for synthesizing the resveratrol derivative of claim 1 wherein Ri = -OH and R2 = R3 = -OCH3, comprising the following steps:
5a 6
14b -*■ 14d (£)
90%
14e,f 14g,
34
7. A method for synthesizing the resveratrol derivative of claim 2 comprising the following steps:
4a (Z),4b(£)
9a
1398874.1/12504.012 35
8. A method for synthesizing the resveratrol derivative of claim 3 comprising the following steps:
9a
5b
14b - 14d (E)
90%
37
9. A method for synthesizing the resveratrol derivative of claim 4 wherein Rio = Ri ι = -OCH3 and Rι2 = -O(PO)(OBn)2, comprising the following steps:
14b * 14d (£)
90%
14e,f 14g,h
10. A method for synthesizing the resveratrol derivative of claim 4 wherein Rio = Ri 1 -OCH3 and -O(PO)(ONa)2, comprising the following steps:
Λa (Z),4b(-=)
9a
14b „»B ' 4 (E) 90%
11. A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof.
12. A pharmaceutical composition comprising the compound of claim 2, or a pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition comprising the compound of claim 3, or a pharmaceutically acceptable salt thereof.
14. A pharmaceutical composition comprising the compound of claim 4, or a pharmaceutically acceptable salt thereof.
15. A method for treating humans and mammals afflicted with cancer, comprising administering a physiologically effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof.
1398874.1/12504.012 42
16. A method for treating humans and mammals afflicted with cancer, comprising administering a physiologically effective amount of the compound of claim 2, or a pharmaceutically acceptable salt thereof.
17. A method for treating humans and mammals afflicted with cancer, comprising administering a physiologically effective amount of the compound of claim 3, or a pharmaceutically acceptable salt thereof.
18. A method for treating humans and mammals afflicted with cancer, comprising administering a physiologically effective amount of the compound of claim 4, or a pharmaceutically acceptable salt thereof.
1398874.1/12504.012 43
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/510,675 US7705188B2 (en) | 2002-04-10 | 2003-04-10 | Structural modification of resveratrol: sodium resverastatin phosphate |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37178202P | 2002-04-10 | 2002-04-10 | |
US60/371,782 | 2002-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003086414A1 true WO2003086414A1 (en) | 2003-10-23 |
Family
ID=29250742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/011008 WO2003086414A1 (en) | 2002-04-10 | 2003-04-10 | Structural modification of resveratrol: sodium resverastatin phosphate |
Country Status (2)
Country | Link |
---|---|
US (1) | US7705188B2 (en) |
WO (1) | WO2003086414A1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006029483A1 (en) * | 2004-09-14 | 2006-03-23 | Ajinomoto Omnichem S.A. | Phosphorylated polyphenols as colour-stable agents |
WO2006029484A1 (en) * | 2004-09-14 | 2006-03-23 | Ajinomoto Omnichem S.A. | Topical compositions containing phosphorylated polyphenols |
EP1748767A1 (en) * | 2004-05-28 | 2007-02-07 | Unigen Pharmaceuticals, Inc. | Diarylalkanes as potent inhibitors of binuclear enzymes |
WO2008012321A1 (en) * | 2006-07-28 | 2008-01-31 | Clariant Specialty Fine Chemicals (France) | Novel process for the synthesis of (e)-stilbene derivatives which makes it possible to obtain resveratrol and piceatannol |
CN100567309C (en) * | 2007-06-15 | 2009-12-09 | 中国科学院广州化学研究所 | (E) 3, 5-dimethoxystilbene-4'-0-phosphate and its preparation, pharmaceutical composition and use |
US8362305B2 (en) | 2008-07-21 | 2013-01-29 | Unigen, Inc. | Series of skin whitening (lightening) compounds |
US8399714B2 (en) | 2007-10-03 | 2013-03-19 | Clariant Speciality Fine Chemicals (France) | Process for the synthesis of polyhydroxystilbene compounds |
US8586799B2 (en) | 2011-03-24 | 2013-11-19 | Unigen, Inc. | Compounds and methods for preparation of diarylpropanes |
CN103992212A (en) * | 2014-05-29 | 2014-08-20 | 河北科技大学 | Synthesis method for cis-benvitimod, and applications of cis-benvitimod |
CN104844517A (en) * | 2015-04-15 | 2015-08-19 | 上海应用技术学院 | (E)-3-hydroxy-5-(hydroxystyryl)imidazole phenol acetate and preparation method and application thereof |
CN104844505A (en) * | 2015-04-15 | 2015-08-19 | 上海应用技术学院 | (E)-3-hydroxy-5-(hydroxystyryl)pyridine-2-phenol formate and preparation method and application thereof |
CN108689805A (en) * | 2018-05-22 | 2018-10-23 | 荆楚理工学院 | A kind of preparation method of resveratrol |
JP2020514249A (en) * | 2016-11-30 | 2020-05-21 | コンセホ・スペリオール・デ・インベスティガシオネス・シエンティフィカスConsejo Superior De Investigaciones Cientificas | Silylated derivatives of resveratrol and their use in neurodegenerative, neurological or inflammatory diseases |
US11174291B2 (en) | 2015-02-13 | 2021-11-16 | Arizona Board Of Regents On Behalf Of Arizona State University | Silstatin compounds |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070292545A1 (en) * | 2005-10-18 | 2007-12-20 | Aaron Monte | Anti-infective agents and methods of use |
WO2008070872A1 (en) * | 2006-12-07 | 2008-06-12 | Rutgers, The State University Of New Jersey | Prevention and treatment of colon cancer |
WO2009038731A2 (en) * | 2007-09-17 | 2009-03-26 | The Trustees Of Columbia University In The City Of New York | Synthesis of resveratrol-based natural products |
WO2010141107A1 (en) * | 2009-06-01 | 2010-12-09 | Aptuit Laurus Private Limited | Solid forms of pterostilbene |
ITRM20130135A1 (en) | 2013-03-06 | 2014-09-07 | Michele Azzolini | NEW RESVERATROLO DERIVATIVES. |
US10138423B1 (en) | 2017-05-31 | 2018-11-27 | International Business Machines Corporation | Resveratrol-based flame retardant materials |
US11629167B2 (en) | 2017-11-09 | 2023-04-18 | Arizona Board Of Regents On Behalf Of Arizona State University | Betulastatin compounds |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060774A1 (en) * | 2000-02-16 | 2001-08-23 | Brigham Young University | Synthesis of resveratrol |
US20020028852A1 (en) * | 1999-09-21 | 2002-03-07 | Geetha Ghai | Resveratrol analogs for prevention of disease |
US20030118617A1 (en) * | 2001-12-21 | 2003-06-26 | Avon Products, Inc. | Resveratrol analogues |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6197834B1 (en) * | 1998-09-01 | 2001-03-06 | Northeastern Ohio Universities College Of Medicine | Method of inhibiting formation of infectious herpes virus particles |
AU2001296215A1 (en) * | 2000-07-17 | 2002-01-30 | Oxi-Gene, Inc. | Efficient method of synthesizing combretastatin a-4 prodrugs |
-
2003
- 2003-04-10 US US10/510,675 patent/US7705188B2/en not_active Expired - Fee Related
- 2003-04-10 WO PCT/US2003/011008 patent/WO2003086414A1/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020028852A1 (en) * | 1999-09-21 | 2002-03-07 | Geetha Ghai | Resveratrol analogs for prevention of disease |
WO2001060774A1 (en) * | 2000-02-16 | 2001-08-23 | Brigham Young University | Synthesis of resveratrol |
US20030118617A1 (en) * | 2001-12-21 | 2003-06-26 | Avon Products, Inc. | Resveratrol analogues |
Non-Patent Citations (7)
Title |
---|
CUSHMAN ET AL.: "Synthesis and evaluation of analogs of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents", JOURNAL OF MEDICINAL CHEMISTRY, vol. 35, no. 12, June 1992 (1992-06-01), pages 2293 - 2306, XP000571677 * |
GRACZA ET AL.: "High-performance liquid chromatographic separation and quantitative determination of plant stilbene derivatives", JOURNAL OF CHROMATOGRAPHY, vol. 287, no. 2, April 1984 (1984-04-01), pages 462 - 465 * |
PETTIT ET AL.: "Antineoplastic agents. 465. Structural modification of resveratrol: Sodium resverastatin phosphate", JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 12, May 2002 (2002-05-01), pages 2534 - 2542, XP002968964 * |
RIMANDO ET AL.: "Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occuring analogue of resveratrol", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 50, no. 12, June 2002 (2002-06-01), pages 3453 - 3457, XP002968963 * |
RYU ET AL.: "Antitumor activity of some phenolic components in plants", ARCH. PHARM. RES., vol. 17, no. 1, January 1994 (1994-01-01), pages 42 - 44, XP002968965 * |
SPATH ET AL.: "Constituents of red sandalwood. III. Synthesis of pterostilbene", BER., vol. 74B, February 1941 (1941-02-01), pages 189 - 192, XP002968966 * |
TAKAOKA MICHIO: "The synthesis of resveratrol and its derivatives", PROCEEDINGS OF THE IMPERIAL ACADEMY, vol. 16, October 1940 (1940-10-01), TOKYO, pages 405 - 407, XP002968962 * |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7767661B2 (en) | 2004-05-28 | 2010-08-03 | Unigen Pharmaceuticals, Inc. | Diarylalkanes as potent inhibitors of binuclear enzymes |
US9126913B2 (en) | 2004-05-28 | 2015-09-08 | Unigen, Inc. | Diarylalkanes as potent inhibitors of binuclear enzymes |
EP1748767A1 (en) * | 2004-05-28 | 2007-02-07 | Unigen Pharmaceuticals, Inc. | Diarylalkanes as potent inhibitors of binuclear enzymes |
US10548825B2 (en) | 2004-05-28 | 2020-02-04 | Unigen, Inc. | Diarylalkanes as potent inhibitors of binuclear enzymes |
US8729136B2 (en) | 2004-05-28 | 2014-05-20 | Unigen, Inc. | Diarylalkanes as potent inhibitors of binuclear enzymes |
US8592488B2 (en) | 2004-05-28 | 2013-11-26 | Unigen, Inc. | Diarylalkanes as potent inhibitors of binuclear enzymes |
EP1748767A4 (en) * | 2004-05-28 | 2008-12-24 | Unigen Pharmaceuticals Inc | Diarylalkanes as potent inhibitors of binuclear enzymes |
CN101018554B (en) * | 2004-09-14 | 2010-10-27 | 味之素欧姆尼凯姆股份有限公司 | Topical compositions containing phosphorylated polyphenols |
AU2004323347B2 (en) * | 2004-09-14 | 2011-02-24 | Ajinomoto Omnichem S.A. | Topical compositions containing phosphorylated polyphenols |
JP2008513378A (en) * | 2004-09-14 | 2008-05-01 | アジノモト オムニケム エッス.アー. | Topical composition containing phosphorylated polyphenols |
WO2006029483A1 (en) * | 2004-09-14 | 2006-03-23 | Ajinomoto Omnichem S.A. | Phosphorylated polyphenols as colour-stable agents |
US8465973B2 (en) | 2004-09-14 | 2013-06-18 | Estee Lauder Coordination Center N.V. | Topical compositions containing phosphorylated polyphenols |
WO2006029484A1 (en) * | 2004-09-14 | 2006-03-23 | Ajinomoto Omnichem S.A. | Topical compositions containing phosphorylated polyphenols |
EP2202215A3 (en) * | 2006-07-28 | 2010-09-08 | Clariant Specialty Fine Chemicals (France) | Novel process for the synthesis of (E)-Stilbene derivatives which makes it possible to obtain resveratrol and piceatannol |
US8101804B2 (en) | 2006-07-28 | 2012-01-24 | Clariant Specialty Fine Chemicals (France) | Process for the synthesis of (E)-stilbene derivatives which makes it possible to obtain resveratrol and piceatannol |
JP2009544663A (en) * | 2006-07-28 | 2009-12-17 | クラリアント スペシャルティー ファイン ケミカルズ(フランス) | Novel process for the synthesis of (E) -stilbene derivatives that makes it possible to obtain resveratrol and piceatannol |
FR2904311A1 (en) * | 2006-07-28 | 2008-02-01 | Clariant Specialty Fine Chem | NEW PROCESS FOR THE SYNTHESIS OF (E) STILBENIC DERIVATIVES PERM TO OBTAIN RESVERATROL AND PICEATANNOL |
EP2202215A2 (en) * | 2006-07-28 | 2010-06-30 | Clariant Specialty Fine Chemicals (France) | Novel process for the synthesis of (E)-Stilbene derivatives which makes it possible to obtain resveratrol and piceatannol |
WO2008012321A1 (en) * | 2006-07-28 | 2008-01-31 | Clariant Specialty Fine Chemicals (France) | Novel process for the synthesis of (e)-stilbene derivatives which makes it possible to obtain resveratrol and piceatannol |
CN100567309C (en) * | 2007-06-15 | 2009-12-09 | 中国科学院广州化学研究所 | (E) 3, 5-dimethoxystilbene-4'-0-phosphate and its preparation, pharmaceutical composition and use |
US8399714B2 (en) | 2007-10-03 | 2013-03-19 | Clariant Speciality Fine Chemicals (France) | Process for the synthesis of polyhydroxystilbene compounds |
US9096507B2 (en) | 2008-07-21 | 2015-08-04 | Unigen, Inc. | Series of skin whitening (lightening) compounds |
US8658838B2 (en) | 2008-07-21 | 2014-02-25 | Unigen, Inc. | Series of skin whitening (lightening) compounds |
US8362305B2 (en) | 2008-07-21 | 2013-01-29 | Unigen, Inc. | Series of skin whitening (lightening) compounds |
US8586799B2 (en) | 2011-03-24 | 2013-11-19 | Unigen, Inc. | Compounds and methods for preparation of diarylpropanes |
US9045405B2 (en) | 2011-03-24 | 2015-06-02 | Unigen, Inc. | Compounds and methods for preparation of diarylpropanes |
CN103992212B (en) * | 2014-05-29 | 2015-07-01 | 河北科技大学 | Synthesis method for cis-benvitimod, and applications of cis-benvitimod |
CN103992212A (en) * | 2014-05-29 | 2014-08-20 | 河北科技大学 | Synthesis method for cis-benvitimod, and applications of cis-benvitimod |
US11174291B2 (en) | 2015-02-13 | 2021-11-16 | Arizona Board Of Regents On Behalf Of Arizona State University | Silstatin compounds |
CN104844517A (en) * | 2015-04-15 | 2015-08-19 | 上海应用技术学院 | (E)-3-hydroxy-5-(hydroxystyryl)imidazole phenol acetate and preparation method and application thereof |
CN104844505A (en) * | 2015-04-15 | 2015-08-19 | 上海应用技术学院 | (E)-3-hydroxy-5-(hydroxystyryl)pyridine-2-phenol formate and preparation method and application thereof |
JP2020514249A (en) * | 2016-11-30 | 2020-05-21 | コンセホ・スペリオール・デ・インベスティガシオネス・シエンティフィカスConsejo Superior De Investigaciones Cientificas | Silylated derivatives of resveratrol and their use in neurodegenerative, neurological or inflammatory diseases |
JP7082977B2 (en) | 2016-11-30 | 2022-06-09 | コンセホ・スペリオル・デ・インベスティガシオネス・シエンティフィカス(セエセイセ) | Resveratrol silylated derivatives and their use in neurodegenerative, neurological, or inflammatory diseases |
US11365208B2 (en) | 2016-11-30 | 2022-06-21 | Consejo Superior De Investigaciones Cientificas | Silylated derivatives of resveratrol and the use thereof in neurodegenerative, neurological or inflammatory diseases |
CN108689805A (en) * | 2018-05-22 | 2018-10-23 | 荆楚理工学院 | A kind of preparation method of resveratrol |
CN108689805B (en) * | 2018-05-22 | 2021-08-03 | 荆楚理工学院 | Preparation method of resveratrol |
Also Published As
Publication number | Publication date |
---|---|
US7705188B2 (en) | 2010-04-27 |
US20050240062A1 (en) | 2005-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7705188B2 (en) | Structural modification of resveratrol: sodium resverastatin phosphate | |
Pettit et al. | Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6 | |
Lee et al. | Preferential cytotoxicity of caffeic acid phenethyl ester analogues on oral cancer cells | |
Cirla et al. | Combretastatins: from natural products to drug discovery | |
Mukherjee et al. | Synthetic and biological activity evaluation studies on novel 1, 3-diarylpropenones | |
Ahmed | Chemistry of natural products | |
Onegi et al. | Antiplasmodial activity of naphthoquinones and one anthraquinone from Stereospermum kunthianum | |
de CF Gomes et al. | Synthetic derivatives of curcumin and their activity against Leishmania amazonensis | |
Flores et al. | Antiparasitic activity of prenylated benzoic acid derivatives from Piper species | |
Wijeratne et al. | A new dihydroxanthenone from a plant-associated strain of the fungus Chaetomium globosum demonstrates anticancer activity | |
Mihigo et al. | Total synthesis, antiprotozoal and cytotoxicity activities of rhuschalcone VI and analogs | |
Abbasi et al. | Curcumin and its derivatives: Moderate inhibitors of acetylcholinesterase, butyrylcholinesterase and trypsin | |
Sarg et al. | Two new polyphenolic compounds from Ficus retusa L.“variegata” and the biological activity of the different plant extracts | |
Pettit et al. | E-Combretastatin and E-resveratrol structural modifications: Antimicrobial and cancer cell growth inhibitory β-E-nitrostyrenes | |
Sriphana et al. | Cytotoxicity of chemical constituents from the roots of Knema globularia | |
Motiur Rahman et al. | Linear diarylheptanoids as potential anticancer therapeutics: synthesis, biological evaluation, and structure–activity relationship studies | |
Jung et al. | Additional bioactive heptenes from Melodorum fruticosum | |
Tietze et al. | Synthesis of highly functionalized anthraquinones and evaluation of their antitumor activity | |
Dobhal et al. | Ferulic acid esters from Plumeria bicolor | |
Al-Rehaily et al. | Bioactive Chemical Constituents of Ononis natrix. | |
Jung et al. | New Synthetic Routes to Biologically Interesting Geranylated Flavanones and Geranylated Chalcones: First Total Synthesis of (±)‐Prostratol F, Xanthoangelol, and (±)‐Lespeol | |
Yousaf et al. | A 5-alkylresorcinol and three3, 4-dihydroisocoumarins derived from Ononis natrix | |
de Jesus Correia et al. | Alkyl phenols and derivatives from Tapirira obtusa | |
Pettit et al. | Antineoplastic agents 460. Synthesis of combretastatin A‐2 prodrugs | |
El-Shazly et al. | Insights on the Isolation, biological activity and synthetic protocols of enyne derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10510675 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |